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Michael S. Samuel16,17, J. Guy Lyons18,19,20, Andrew Burgess21,22, C. Elizabeth Caldon1,2,  
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Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic, chemoresistant malignancy and is characterized 
by a dense, desmoplastic stroma that modulates PDAC progression. Here, we visualized transient manipulation of 
focal adhesion kinase (FAK), which integrates bidirectional cell-environment signaling, using intravital fluorescence 
lifetime imaging microscopy of the FAK-based Förster resonance energy transfer biosensor in mouse and 
patient-derived PDAC models. Parallel real-time quantification of the FUCCI cell cycle reporter guided us to 
improve PDAC response to standard-of-care chemotherapy at primary and secondary sites. Critically, micro-
patterned pillar plates and stiffness-tunable matrices were used to pinpoint the contribution of environmental 
cues to chemosensitization, while fluid flow–induced shear stress assessment, patient-derived matrices, and 
personalized in vivo models allowed us to deconstruct how FAK inhibition can reduce PDAC spread. Last, stratifi-
cation of PDAC patient samples via Merlin status revealed a patient subset with poor prognosis that are likely to 
respond to FAK priming before chemotherapy.
INTRODUCTION
Despite improvements in drug discovery and therapeutic efficacy, 
pancreatic ductal adenocarcinoma (PDAC) remains one of the 
most lethal cancers worldwide (1). While the addition of nab-paclitaxel 
(Abraxane) to traditional gemcitabine monotherapy improved 
median patient survival by ~6 weeks, the overall 5-year survival rate 
has remained virtually stagnant at <10% for the past four decades 
(1, 2). A substantial proportion of patients with PDAC present with 
metastatic disease at the time of diagnosis, and once metastasized, 
the 5-year survival further decreases to a dismal 3% (1, 2). PDAC 
formation and progression are accompanied by the deposition of 
a dense desmoplastic extracellular matrix (ECM) or stroma that 
increases the biomechanical force load on cancer cells and is thought 
to both promote and restrict disease advancement (3–5). While 
complete ablation of stromal components has been shown to reduce 
survival, recent studies focusing on the transient targeting of the stroma 
have proven promising because of the subtle alterations that this approach 
can induce on tissue architecture, stiffness, or mechanoplasticity in 
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PDAC (3, 4, 6–11). Hence, there is a need to deconstruct the clinical 
benefits of transient versus chronic stromal manipulation while 
optimizing epithelial targeting before chemotherapy to obtain the 
maximal outcome in this disease.
Focal adhesion kinase [FAK or PTK2 (protein tyrosine kinase 2)] is 
a ubiquitously expressed nonreceptor tyrosine kinase that mediates 
communication between cells and their environment (12). It regu-
lates bidirectional integrin-mediated “inside-out and outside-in 
signaling” (13, 14) and is often hyperactivated and overexpressed in 
multiple aggressive cancers (12, 13, 15). The reciprocal interactions 
between cancer cells and their surrounding stromal architecture 
drive signaling pathways that have been shown to promote matrix 
remodeling; induce tissue stiffness; and accelerate cell proliferation, 
cell survival, and disease progression (14, 16–18). Thus, under-
standing and optimizing the individual responses of cancer and 
stromal cells to FAK inhibition (hereafter referred to as epithelial 
and stromal targeting, respectively), rather than epithelial cell 
targeting alone, may provide insights into potential therapeutic 
regimens to combat this aggressive disease at the intersection of 
tumor-stromal cross-talk.
An important step in the clinical management of disease is the 
ability to match a selective drug target with a specific molecular 
signature that may predict drug sensitivity (19). The canonical 
tumor suppressor, Merlin (NF2), has been shown to regulate the 
function and activity of cell surface receptor tyrosine kinases, 
modulating “outside-in” signaling to control contact-induced inhibi-
tion of proliferation and tumor progression in various cancer types 
(20–22). In preclinical models (20) and clinical studies (21) in a 
diverse panel of cancers, enhanced efficiency of FAK inhibitors 
(FAKi) was observed in tumors harboring reduced Merlin levels; 
however, a correlation between Merlin expression and FAKi sensitivity 
in PDAC remains to be assessed.
Intravital imaging provides insight into how epithelial and 
stromal cells behave in the native tumor microenvironment, allowing 
optimization of therapeutic response in real time (23–26). Here, we 
use well-validated primary pancreatic cancer (PC) cells derived 
from the aggressive metastatic KPC (Pdx1-Cre, LSL-KrasG12D/+, 
LSL-Trp53R172H/+) mouse model of PDAC, which retain their 
invasive and metastatic capacity ex vivo (18, 26–29), and patient- 
derived cell lines (PDCLs) from the Australian Pancreatic Genome 
Initiative (APGI) to dissect and optimize the benefits of stromal and 
epithelial targeting in this disease (18, 30–32). We used the FAK-based 
Förster resonance energy transfer (FRET) biosensor (33) or the 
Fluorescent ubiquitination-based cell cycle indicator (FUCCI) cell 
cycle reporter (34) for in vivo imaging to monitor dynamic changes 
in FAK activity and gemcitabine/Abraxane-induced effects on KPC 
cell cycle distribution, respectively. This imaging approach allowed 
us to optimize treatment response at both primary and secondary 
sites in live tissue. Following pulsed FAKi priming, we reveal subtle 
changes in the ultrastructure of the ECM architecture along with 
changes in both FAK activity and cell cycle distribution following 
gemcitabine/Abraxane chemotherapy in live primary tumors and 
at secondary sites within the liver. Using micropatterned pillar plates 
and stiffness-tunable matrices, we elucidate how the mechanics 
of the microenvironment contribute to this chemosensitization. 
In parallel, cell streaming, personalized organotypic assays, and fluid 
flow–induced shear stress assessment allowed us to deconstruct and 
streamline stromal and epithelial FAK inhibition before chemo-
therapy, highlighting the sensitivity of tumor cells to pulsed FAK 
inhibition during transit, which may ultimately prevent seeding and 
colonization in the metastatic niche. Using long-term orthotopic 
assessment of metastatic burden and survival via tailored targeting of 
PDCLs with high versus low FAK signatures, we reveal a personalized 
response to transient stromal priming via FAK inhibition relative 
to inherent “inside-out” FAK signaling axis status. Furthermore, 
following assessment of a graded response to FAK inhibition, we 
evaluate Merlin expression levels in the context of high versus low 
FAK status in patient settings via the International Cancer Genome 
Consortium (ICGC) cohort (30–32). The capacity to further strati-
fy individual patient response to FAK inhibition using low Merlin 
expression as a potential positive biomarker may provide a promis-
ing guide in the clinical management of PDAC treatment. Togeth-
er, we present preclinical and clinically relevant data that streamline 
stromal and epithelial FAK inhibition to guide ongoing FAK-based 
clinical applications in both the primary and metastatic settings of 
PDAC. Furthermore, we reveal intertumoral heterogeneity within 
pancreatic patient tumors that could tailor FAKi priming before 
standard-of-care chemotherapy in this disease to significantly ab-
late tumor progression based on Merlin status.
RESULTS
FAK expression and activity increase with disease 
progression in the KPC mouse model of PDAC and correlate 
with poor patient prognosis
To evaluate the levels of FAK expression and activity during PDAC 
progression, we initially analyzed autochthonous KPC mouse 
tumors at different stages of disease progression using Picrosirius 
red collagen I and III costaining, coupled with assessment of total 
and phosphorylated (pTyr397) FAK by immunohistochemistry (IHC). 
We found that the expression and activity of FAK increased through 
PDAC disease progression, concomitant with enhanced fibrosis 
(Fig. 1, A to C, and fig. S1, A to C). This was confirmed by immuno-
fluorescence costaining of –smooth muscle actin (SMA) (stroma) 
or E-cadherin (epithelial) and pTyr397-FAK (fig. S1, D and E, 
respectively). In line with this, bulk assessment of FAK (PTK2) 
expression levels in patients with PDAC from the ICGC (267 samples) 
demonstrated that high FAK expression (top 25%) correlated with 
poor survival (Fig. 1, D and E). Moreover, IHC analysis of human 
biopsy tumor microarrays (TMAs) of a cohort of 231 patient samples 
from the APGI further revealed that high stromal pTyr397-FAK was 
also predictive of poor clinical survival in patients with early fibrosis, 
as assessed via costaining with Picrosirius red (Fig. 1F and fig. S1, 
B and C). When quantifying fibrosis via Picrosirius red staining in 
surgical samples of patients with PDAC from the stroma-focused 
Australian Pancreatic Cancer Matrix Atlas (APMA) cohort, we 
observed a significant increase in fibrosis in patients with PDAC 
who received presurgical neoadjuvant gemcitabine/Abraxane 
chemotherapy compared to treatment-naïve patients (fig. S1J). This 
indicates that an early fibrotic stromal reaction is one of the first 
responses to chemotherapy in this disease. To provide a potential 
avenue for optimized FAK targeting regimens and improved outcomes 
in this multifaceted and highly heterogeneous disease, we sought 
to first dissect the role that pharmacological FAK inhibition could 
have on stroma and epithelium in the complex microenvironment of 
pancreatic tumors. As FAK expression and activity levels can vary 
both at the intertumoral patient level and intratumoral levels within 
the tumor’s stromal and epithelial compartments (30–32), tailoring 
Murphy et al., Sci. Adv. 2021; 7 : eabh0363     29 September 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
3 of 27
treatment regimens depending on individual tumor status could 
allow for a personalized approach to FAK targeting in PC.
Deconstructing the benefits of epithelial and stromal  
FAK inhibition in PDAC
As PDAC is a highly aggressive and metastatic cancer, we initially 
assessed the direct effects of pharmacological FAK inhibition on 
cell movement in 2.5-dimensional (2.5D) cell-derived matrices 
(CDMs) using primary cells lines generated from the KPC model of 
PC (27, 35, 36). CDMs were established to provide a high-fidelity 
ECM substrate and platform to examine the effects of FAK inhibi-
tion on coordinated single and collective cell motility in real time 
(Fig. 2A). Following KPC cell adhesion to decellularized matrix, 
KPC cells were treated with the FAKi PF-562271 (FAKi; Fig. 2A and 
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Fig. 1. ECM abundance and FAK expression and activity increase throughout PDAC progression, providing a rationale to target tumor-ECM feedback in PC. 
(A to C) Representative images of normal pancreas, early Pancreatic intraepithelial neoplasia (PanIN), late PanIN, and PDAC tissue (scale bars, 100 m) and quantification 
of collagen I/III coverage (Picrosirius red) (A), phosphorylated (pTyr397) FAK (DAB) (B), and total FAK expression (DAB) (C). n ≥ 3 mice per stage and n ≥ 3 fields of view (FOVs) 
per stage per mouse. Results: means ± SEM. P values were determined using an ordinary one-way analysis of variance (ANOVA) with Tukey correction for multiple 
comparisons, and significance is compared to normal pancreas. (D) Schematic representation of patient-derived xenograft (PDX) and parallel TMA establishment. 
(E) Kaplan-Meier analysis of human PC disease survival based on FAK expression (microarray) with high FAK (red) versus low FAK (blue) in the ICGC cohort. (F) Kaplan-Meier 
analysis of deceased human PC patient survival with low Picrosirius red staining and high pTyr397-FAK (red) versus low pTyr397-FAK (blue) in the APGI cohort. Patients who 
died of surgical complication or whose deaths were non–cancer-related were excluded from the analysis. Significance was determined using a Kaplan-Meier analysis 
of survival compared using a log-rank test. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Fig. 2. Effect of epithelial versus stromal FAK inhibition on single and collective KPC cancer cell migration. (A) Schematic of CDM generation, decellularization, and 
KPC cell seeding. (B) Representative tracks of KPC cell migration on CDMs upon treatment with vehicle or FAKi over 8 hours. (C) Quantification of KPC cell average distance 
traveled, displacement from starting position, speed, and track persistence over 8 hours. (D) Schematic of organized (high anisotropy, top) and unorganized cell migra-
tion (low anisotropy, bottom). (E to G) Representative binary images of KPC cell streaming 72 hours after seeding treated with vehicle or FAKi during migration (E) (arrows 
represent stream directionality; scale bars, 200 m) with quantification of average anisotropy at 36 (F) and 72 hours (G). (H) Schematic of CDM production treated with 
vehicle or FAKi. (I and J) Representative maximum intensity second harmonic generation (SHG) images in CDMs treated with vehicle or FAKi (I) (scale bar, 100 m) with 
quantification of peak SHG signal intensity (J). (K) Schematic of organized (high anisotropy, top) and unorganized cell migration (low anisotropy, bottom). (L to N) Repre-
sentative binary images of KPC cell streaming 72 hours after seeding on vehicle or FAKi-primed CDMs (L) (arrows represent stream directionality; scale bars, 200 m) with 
quantification of average anisotropy at 36 (M) and 72 hours (N). n = 3 biological repeats, 3 CDMs per repeat, 3 FOVs per CDM (15 cells per FOV) (C). Results: 
means ± SEM. P values were determined using an ordinary one-way ANOVA with Tukey correction for multiple comparisons. Unless otherwise stated, all significance is 
compared to vehicle. ns, P > 0.05; **P < 0.01, and ***P < 0.001. AU, arbitrary units.
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fig. S1, F and G) (12, 37), and individual cell tracking demonstrated 
a significant reduction in average distance traveled, track displace-
ment, migratory speed, and track persistence of cells compared to 
control settings (Fig. 2, B and C). In addition, assessing cell orientation 
relative to a wound revealed that this may, in part, be due to a loss 
of cell polarity upon FAKi treatment indicated by a loss of the cells’ 
ability to orientate the Golgi body to the leading edge of the cell, as 
previously described (fig. S1, H and I) (38, 39).
Next, we assessed collective cell migration or “streaming” in 
this setting, which more faithfully recapitulates tumor cell motility 
and invasion found in  vivo. Here, we used image anisotropy to 
quantify the coordinated nature of cell migration, which can often 
facilitate a more efficient mode of invasion, whereby cells collec-
tively move in the same direction and follow a stream of least 
resistance (see schematic in Fig. 2D) (18, 40, 41). Image anisotropy 
analysis was performed over a 72-hour period, where “high anisotropy” 
indicated collective coordinated migration between cancer cells 
and “low anisotropy” indicated uncoordinated migration, as 
recently described (Fig. 2D) (18, 42). This revealed that while FAK 
inhibition altered individual KPC cell migration on CDMs (Fig. 2, 
A to C), collective cell movement was not significantly changed 
when targeting the epithelial tumor cells alone (Fig. 2, D to G, and 
movie S1).
As well as neighboring cells influencing cancer cell movement, 
cancer cells also bias their locomotive direction with guidance from 
external cues such as the local ECM (43–45). We therefore assessed 
whether targeting the ECM via stromal FAK inhibition could affect 
collective cancer cell migration. Here, fibroblasts were treated with 
FAKi during CDM production (“priming”) before subsequent FAKi 
washout (Fig. 2H). Following fibroblast removal and FAKi washout, 
second harmonic generation (SHG) imaging permitted visualization 
and quantification of cross-linked collagen, demonstrating that 
short-term stromal targeting with FAKi significantly reduced the 
ability of fibroblasts to produce mature and cross-linked collagen 
compared to control [Fig. 2, I and J (confirmed by Picrosirius red 
staining) and fig. S2, A and B].
Highly aligned linear matrix fibers serve as migratory routes for 
cells and are well suited to resisting tensile forces in the alignment 
direction, whereas a disorganized ECM network is thought to 
compromise cell migration and tissue mechanics. To assess alterations 
in the architectural patterns of the fibroblast-derived ECM of 
CDMs, matrices were fixed and stained with Picrosirius red before 
polarized light imaging. Analysis of the birefringent signal revealed 
a decrease in total fibrillar collagen content upon treatment with 
FAKi (fig. S2, C to E). Further analysis of matrix alignment using 
FibrilTool (42) showed a decrease in matrix anisotropy upon FAKi 
treatment (fig. S2, F and G). Global matrix organization upon FAKi 
was further assessed using the ImageJ plugin TWOMBLI (46), which 
highlighted notable differences in addition to fibrillar alignment 
(fig. S2H). Here, while we observed no change in fibrillar curvature 
(mean change in angle along a fiber; fig. S2I; please also see inset in 
fibrillar analysis masks in fig. S2H), larger gaps and increased 
porosity in control matrices were reflected in the higher lacunarity 
and lower fractal dimension compared to FAKi-treated matrices 
(fig. S2, J and K). Analysis of individual fiber organization showed a 
shift from an anisotropic organized matrix, commonly associated 
with aggressive cancers (47), to an isotropic and poorly organized 
matrix upon treatment with FAKi. Here, we revealed that FAKi 
during CDM matrix production led to an increase in the normalized 
number of fiber branches and endpoints and a corresponding 
decrease in hyphal growth unit (a measure of the number of end-
points per unit length; fig. S2, L to N). Collectively, this analysis 
shows that stromal FAKi treatment can disrupt distinct aspects of 
ECM deposition, remodeling, and organization.
To assess whether this change in matrix deposition and remodeling 
altered subsequent KPC cell migration, KPC cells were next seeded 
onto control versus FAKi-pretreated or “primed” matrices. Analysis 
of individual cell movement on FAKi-primed matrices showed no 
significant change in cell velocity (average speed; fig. S2O), while 
the directionality of cell movement (average persistence) was sig-
nificantly reduced for individual cells on FAKi-treated matrices 
(fig. S2P). Moreover, quantification of KPC cell streaming revealed 
that on matrices that had been primed with FAKi during early ECM 
deposition, cell streaming and collective migration of cancer cells 
were decreased, with cells moving in an uncoordinated and in-
efficient manner compared to vehicle priming (Fig. 2, K to N, and 
movie S2). This disruption of outside-in signaling from the ECM 
indicated an additional dependence of cancer cells on the surrounding 
stromal microenvironment to coordinate collective cell migration. 
Collective cell movement is often observed in  vivo at the leading 
edge of tumors (40, 41) and can play a key role in driving directional 
invasion before metastatic spread. Hence, we opted to mimic this 
spatially coordinated cancer cell invasion in response to FAKi in 
live 3D cocultures using organotypic assays (18, 26, 28, 48, 49).
Transient matrix priming impairs PDAC invasion and is more 
effective than chronic treatment
Organotypic invasion assays (Fig. 3, A to C) enable the assessment 
of reciprocal interactions between cancer cells and fibroblasts in a 
3D collagen-rich environment (18, 26, 28, 48, 49). Here, a 3D-fibrillar 
collagen matrix is remodeled, cross-linked, and contracted over 
12 days by fibroblasts, allowing us to readily assess stromal targeting 
effects in this disease (see schematic in Fig. 3A). Once formed, 
PDAC cells are seeded on top of this matrix and then exposed to an 
air-liquid interface from which they can readily interact with live 
fibroblasts and the ECM during invasion toward a chemotactic 
gradient (Fig.  3,  B  and  C). In this way we can understand and 
deconstruct the stromal versus epithelial responses to FAKi treatment. 
Fibroblast-driven contraction in the presence of FAKi or vehicle 
revealed a decrease in matrix contraction (Fig. 3, D to F). Using 
multiphoton-based fluorescence lifetime imaging microscopy 
(FLIM)– FRET of a reversible FAK biosensor expressed in the 
stromal cells (33), we could also visualize FAK activation status 
within these matrices in real time during this process (Fig. 3, G to I). 
Here, low FAK activity in fibroblasts is displayed in the fluorescence 
lifetime maps as “cold” blue/green colors indicative of shorter life-
times, whereas high FAK activity is represented by longer lifetimes 
and “warm” yellow/red colors (Fig. 3I). Using FLIM-FRET imaging 
to assess target validation during collagen contraction revealed an 
increase in FAK activity over the course of matrix remodeling, con-
firming a critical role for FAK in this process, which was reduced in 
response to FAKi in this live 3D setting (compare vehicle at days 1, 
7, and 12 progressively increasing in lifetime/activity, which was 
impaired under FAKi conditions; Fig. 3, H and I). The reduced 
contraction of matrices was independent of changes to fibroblast 
survival or proliferation during this time, as assessed using cleaved 
caspase-3 (CC3) and Ki67 IHC staining within matrices (fig. S3, 
A and B). Furthermore, SHG imaging demonstrated that FAKi altered 
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Fig. 3. Stromal FAKi priming reduces fibroblast-driven collagen remodeling and KPC cancer cell invasion into organotypic matrices. (A to C) Schematic of 3D 
organotypic invasion assay: Fibroblast-driven collagen contraction (A), cancer cell seeding (B), and invasion into the contracted matrix toward the chemotactic gradient, 
created by air-liquid interface [note the culture medium meniscus (where cells remain in contact with media)] (C). (D) Schematic representation of fibroblast-mediated 
collagen matrix contraction upon vehicle or FAKi priming. (E and F) Quantification (E) and representative images (F) (scale bars, 5 mm) of matrix contraction over time. 
(G) Schematic of the FAK-FRET biosensor. (H and I) Quantification (H) and representative intensity-merged maps of ECFP fluorescence lifetime (I) in fibroblasts during 
matrix remodeling. Scale bar, 100 m. (J and K) Representative maximum intensity SHG projections in fibroblast-contracted matrices (J) (scale bars, 100 m) with quantification 
of SHG signal intensity (K) at peak (left) and over depth (in m; right). (L) Schematic representation of organotypic invasion assay with late epithelial treatment (during 
KPC cell invasion), FAKi priming (during matrix contraction), and chronic treatment (during matrix contraction and invasion). (M and N) Quantification of KPC cell invasion 
(M) (normalized cell number at >200-m depth) with representative images of pan-cytokeratin–stained KPC cells (N) (dotted line, 200-m invasion depth; scale bars, 
50 m). n = 3 biological repeats, with three matrices per repeat and three FOVs per matrix (D to N). n = 20 cells per condition per replicate (H and I). Results: 
means ± SEM. P values were determined using an ordinary one-way ANOVA with Tukey correction for multiple comparisons. Unless otherwise stated, all significance is 
compared to vehicle. ns, P > 0.05; *P < 0.05, **P < 0.01, and ***P < 0.001.
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the ultrastructure of the ECM in this context by reducing collagen 
cross-linking and remodeling (Fig. 3, J and K, and movie S3), which 
was confirmed with Picrosirius red–based polarized light imaging 
(fig. S3, C to G) (50) and gray-level co-occurrence matrix (GLCM) 
analysis (fig. S3, H to K) (47), which both confirmed the reduced 
birefringence and organization of the matrix after FAK inhibition, 
respectively. Quantification of raw high, medium, and low bire-
fringent Picrosirius red signal (indicative of a range from mature to 
immature collagen fibers) showed a significant decrease in low 
birefringent signal (indicative of immature collagen fibers) upon 
FAKi treatment, suggesting that FAKi could also reduce new matrix 
production, deposition, and early remodeling of nascent fibers by 
the fibroblasts in addition to the decrease in established cross-linking 
that we see with SHG imaging (fig. S3E). Last, biomechanical 
measurements also revealed that FAKi reduced matrix stiffness 
as measured by compression and shear rheology analysis (fig. 
S3, L and M) (51).
Given the effects on ECM deposition, remodeling, and stiffness 
upon FAKi priming, we next assessed whether transient matrix 
manipulation to alter outside-in signaling was sufficient to impair 
cancer cell invasion. Organotypic matrices were treated with vehicle 
or FAKi during contraction only (early stromal FAKi priming), 
during invasion only (late epithelial treatment), or during both 
contraction and invasion in a chronic treatment setting (Fig. 3L). 
Late epithelial treatment alone slightly decreased cell invasion 
in a dose-dependent manner (compare column 1 to 2 and 3; Fig. 3, 
M and N), in line with our previous results for KPC cell migration 
on CDMs (Fig. 2, B and C), while priming of the stroma before 
cancer cell seeding significantly decreased KPC cell invasion into 
the matrix that was not improved upon in a chronic treatment 
setting (compare column 1 with 4 to 7; Fig. 3, M and N) and was 
independent of changes in cancer cell proliferation or apoptosis 
(fig. S3, N and O). This demonstrated that short-term stromal FAKi 
priming can efficiently impair cancer cell invasion, while reducing 
the need for chronic treatment regimens, which can often lead to 
side effects in the case of stromal targeting (3, 7) and opens up 
previously unidentified opportunities for less off-target effects in 
combination therapy in PC (3, 7, 12, 16, 18, 26, 52, 53). We therefore 
sought to examine whether short-term FAKi priming of the stroma 
could improve the outcome of standard-of-care chemotherapy in PC.
FAKi priming improves response to gemcitabine/Abraxane
Biomechanical input and ECM–cancer cell feedback have previously 
been shown to promote resistance to standard-of-care chemothera-
pies (5, 6, 54–56). As short-term stromal priming before invasion 
had a significant effect on the migratory capacity of KPC cells 
(Fig. 3, M and N) with the potential to minimize the need for chronic 
administration, we next investigated whether transient matrix 
manipulation by FAKi would sensitize KPC cells to subsequent 
standard-of-care gemcitabine/Abraxane in organotypic matrices 
(Fig. 4, A and B). CC3 and Ki67 staining in 3D-organotypic assays 
revealed that gemcitabine/Abraxane treatment alone increased 
KPC cell apoptosis and reduced cell proliferation in line with its 
clinical applications (Fig. 4, C to F, dark gray graphs versus hash gray 
graphs) (2). Stromal FAKi priming to impair fibroblast-mediated 
remodeling of the ECM, before gemcitabine/Abraxane treatment, 
however, resulted in a significant decrease in KPC cell proliferation 
and increase in KPC cell death compared to vehicle priming and 
gemcitabine/Abraxane treatment alone (Fig. 4, C to F, gray hash 
graphs versus green hash graphs). This effect was not improved 
upon with late FAK inhibition during KPC cell invasion (fig. S3, P to R, 
gray hash graph versus green hash graphs). In this way, short-term 
stromal targeting and matrix priming via FAK inhibition before 
chemotherapy may maximize current standard-of-care efficacy while 
minimizing potential side effects associated with long-term chronic 
stromal treatment. Guided by these data, we next assessed whether 
FAKi priming can improve response to chemotherapy in a live 
tumor setting.
FAKi priming renders cells vulnerable to subsequent 
chemotherapy in live tumors
On the basis of our initial insights from 3D organotypic assays, we 
moved to a live intravital imaging setting to monitor in more detail 
the spatiotemporal response to FAKi priming in vivo. We generated 
FAK biosensor–expressing KPC cancer cells (KPC-FAK) and 
implanted them subcutaneously into mice. Once primary tumors 
were palpable, mice were primed with FAKi for 3 days before intra-
vital imaging (see schematic in fig. S4A) (18, 33). In vivo target 
validation using the FAK biosensor confirmed that short-term FAKi 
priming was sufficient to reduce FAK activity in live tumors (fig. S4, 
A to C, and movie S4) and also decreased ECM deposition and 
remodeling in the stromal compartment in vivo, as assessed by 
SHG imaging (fig. S4D). Using this priming approach, we next 
examined drug response in real time using the FUCCI cell cycle 
reporter in KPC cells (KPC-FUCCI) as a readout of chemotherapeutic 
efficiency, where cells change color (red to green) in real time 
depending on cell cycle stage (31, 34). Following generation of 
palpable KPC-FUCCI tumors, mice were primed as described 
above, with FAKi for 3 days before gemcitabine/Abraxane treatment 
at day 11 (see schematic in Fig. 5A). Live tumor tissues were exposed 
24 hours after chemotherapy and intravitally imaged (Fig. 5, A and B, 
and movie S5). Quantification of the FUCCI cell cycle reporter 
demonstrated that gemcitabine/Abraxane treatment alone resulted 
in a larger proportion of cells in S-G2-M phase compared to control 
[Fig. 5B (red-to-green shift, quantified in Fig. 5C)], as previously 
achieved (31) and in line with clinical applications. Priming with 
FAKi monotherapy revealed a similar increase in the proportion of 
cells in S-G2-M phase compared to control (Fig. 5, B and C), which 
may be due to direct effects of FAK inhibition on KPC tumor cells 
and indirect effects via changes in the tumor ECM architecture. 
Critically, priming with FAKi and subsequent chemotherapy induced 
a significantly larger proportion of cells in S-G2-M compared to 
gemcitabine/Abraxane alone, indicating an enhancement of chemo-
therapeutic efficiency (Fig. 5, B and C). IHC analysis of Ki67 and 
CC3 also confirmed that FAKi priming combined with gemcitabine/
Abraxane reduced cancer cell proliferation and survival in vivo 
(fig. S4, E to H). To evaluate the direct or indirect effect of FAKi 
priming on KPC cells versus the tumor ECM architecture, we next 
aimed to dissect the epithelial and stromal effects of FAKi priming 
on KPC cell cycle distribution.
Matrix stiffness rather than direct epithelial FAK inhibition 
dictates PC cell sensitivity to gemcitabine/Abraxane
SHG imaging along with polarized light microscopy of KPC tumors 
described above demonstrated that FAKi priming alone and before 
chemotherapy significantly reduced cross-linked fibrillar collagen 
deposition and organization (Fig. 5, D and E, and fig. S4, I to L). In 
line with the recognized role of outside-in signaling and ECM- tumor 
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feedback in tumor progression (14, 44, 57), we next dissected the 
effects of epithelial and stromal FAK targeting on cell cycle pro-
gression using (i) the FUCCI biosensor, (ii) pillar plates (58, 59), 
and (iii) stiffness-tunable matrices (60). The mechanoreciprocity 
between tumor cells and their surrounding ECM can influence 
several signaling pathways including those involved in tumor cell 
proliferation and cell cycle progression (6, 43, 57). Hence, the effect 
of matrix stiffness on cell cycle progression and chemotherapeutic 
efficiency was next assessed. Here, KPC-FUCCI cells were seeded 
onto polymethyl methacrylate pillar plates, where the pillar height 
(in nm) determines surface stiffness (58, 59). Shorter pillars are less 
mobile and therefore have a stiffer surface, while taller pillars are 
more pliable and thus present a softer surface (Fig. 5F) (58, 59). 
Here, 72 hours after seeding onto the pillar plates, KPC cells were 
imaged. Analysis of the FUCCI reporter demonstrated that the 
percentage of KPC cells in S-G2-M phase of the cell cycle increased 
in correlation with increasing pillar height and surface softness 
(Fig. 5, G and H). Grouping of the varying pillar heights into either 
stiff and soft (stiff, <112 nm and soft, ≥112 nm) revealed that there 
was a significant increase in the number of KPC cells in the S-G2-M 
phase on soft surfaces compared to stiff surfaces (Fig. 5I). This indi-
cates that softer matrix surfaces can increase the number of KPC 
cells in S-G2-M, which may render them vulnerable to subsequent 
gemcitabine/Abraxane chemotherapy.
To further elucidate whether the observed increase in gemcitabine/
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Fig. 4. Manipulation of tumor-ECM feedback by FAKi priming improves KPC cell sensitivity to gemcitabine/Abraxane in organotypic matrices. (A and B) Schematic 
representation of an organotypic invasion assay where matrices were primed with vehicle (A) or FAKi (B) during contraction followed by FAKi washout, KPC cell seeding, 
11-day invasion without drug treatment, and then 72 hours of gemcitabine (Gem) and Abraxane treatment. (C and D) Representative images of KPC cancer cells, stained 
for CC3 in vehicle or FAKi-primed matrices treated with control or gemcitabine/Abraxane (C) (scale bars, 50 m; zoomed scale bar, 50 m; arrows highlight positive cells) 
with quantification of CC3-positive cells invading into and on top of matrices (D). (E and F) Representative images of KPC cancer cells, stained for Ki67 in vehicle- or 
FAKi-primed matrices treated with control or gemcitabine/Abraxane (E) (scale bars, 50 m; zoomed scale bar, 50 m) with quantification of Ki67-positive cells invading 
into and on top of matrices (F). n = 3 biological repeats, 3 matrices per repeat, and 3 FOVs per matrix for quantification. Results: means ± SEM. P values were determined 
using an ordinary one-way ANOVA with Tukey correction for multiple comparisons. Unless otherwise indicated, significance is compared to vehicle. ns, P > 0.05; *P < 0.05, 
**P < 0.01, and ***P < 0.001.
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Fig. 5. FAKi priming improves KPC tumor response to gemcitabine/Abraxane in vivo, which may partially be driven by a “softening” of the tumor microenvironment. 
(A) Timeline of subcutaneous KPC-FUCCI xenografts with intravital imaging of FUCCI cell cycle reporter in surgically exposed tumors. IP, intraperitoneal. (B and C) Repre-
sentative FUCCI images (B) and quantification (C) in tumors primed with vehicle or FAKi followed by saline or gemcitabine/Abraxane. Scale bars, 50 m. (D and E) Repre-
sentative maximum projections of SHG signal (magenta) and tumor cells (green) (scale bars, 100 m) (D) and quantification of peak SHG signal intensity (E). n = 5 animals 
per treatment group, 15 (B and C) and 5 FOVs (D and E) per animal. (F) Schematic of stiff and soft pillar plates. (G to I) Quantification (G), representative images (H) (scale 
bars, 50 m), and pooled average cell cycle phase distribution (I) of FUCCI reporter in KPC-FUCCI cells grown on pillars of varying heights. Numbers indicate pillar height 
(increasing softness from left to right). Micropatterned cell surface interface differs for repeated pillar heights. n = 3 repeats, 1 height per micropattern per repeat, 5 FOVs 
per replicate. (J) Schematic of cancer cells seeded onto collagen-coated stiff (20 kPa) and soft (2 kPa) hydrogels. (K to N) Representative FUCCI images (K and M) 
(scale bars, 50 m) and quantification (L and N) in KPC-FUCCI cells seeded onto hydrogels treated with vehicle or FAKi followed by saline (K and L) or gemcitabine/
Abraxane (M and N). n = 3 biological repeats, 2 hydrogels per repeat per treatment group, 5 FOVs per gel. Results: means ± SEM. P values were determined using a two-way 
ANOVA (C, I, L, and N) and one-way ANOVA (E) with Tukey correction for multiple comparisons. ns, P > 0.05; *P < 0.05, **P < 0.01, and ***P < 0.001.
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indirectly via changes in matrix ultrastructure and stiffness, KPC 
cells were seeded onto tunable soft or stiff polyacrylamide hydrogels 
(2 and 20 kPa, respectively) (60, 61). Here, the area of direct cancer 
cell–matrix contact is equal, but the surface stiffness varies (see 
schematic in Fig. 5J). After seeding and adhesion to the hydrogels, 
cells were treated with vehicle or FAKi for 72 hours, followed by 
treatment with the vehicle control for gemcitabine/Abraxane for 
24 hours. As before, cells grown on stiff versus soft gels revealed an 
accumulation of cells in S-G2-M in soft conditions (compare vehicle 
stiff and vehicle soft; Fig. 5, K and L). FAKi addition to cancer cells 
on these gels did not enhance this S-G2-M shift any further (com-
pare FAKi stiff versus soft; Fig. 5, K and L). Next, cells were placed 
on stiff or soft hydrogels and subjected to gemcitabine/Abraxane 
for 24 hours after 72 hours of pretreatment and subsequent washout 
of vehicle or FAKi. Analysis of cell cycle distribution indicated by 
the FUCCI reporter revealed (i) that the shift to S-G2-M phase is 
again higher for cancer cells on soft gels than those on stiff surfaces, 
(ii) that gemcitabine/Abraxane increases the baseline number of 
cells in S-G2-M phase for all conditions (stiff and soft; compare 
Fig. 5, K and L, with Fig. 5, M and N), and (iii) that FAKi does not 
enhance the amount of cells in S-G2-M phase any further on both 
stiff and soft matrices in the presence of gemcitabine/Abraxane 
(Fig. 5, M and N). Together, this suggests that reducing matrix 
stiffness, rather than direct epithelial FAK inhibition, may in-
crease KPC cell sensitivity to gemcitabine/Abraxane indirectly via 
stromal targeting and disruption of the ECM architecture, altering 
outside-in signaling and thereby increasing the number of KPC 
cells in S-G2-M, which may improve response to subsequent 
chemotherapy.
Priming with FAKi reduces metastatic spread and  
sensitizes cells to chemotherapy during transit via  
enhanced vulnerability to shear stress and sensitivity 
to anchorage-independent growth
As the majority of patients with PDAC present clinically with locally 
invasive disease, we next investigated the potential of FAKi priming 
with chemotherapy to alter metastatic colonization at secondary 
sites in the liver or during transit (18, 62, 63). To mimic the effects 
of FAKi priming in the presence of circulating tumor cells, intra-
splenic injections were performed using KPC-FUCCI cells in parallel 
with FAKi priming (Fig. 6A). Mice were primed with FAKi for 
3 days during intrasplenic injection of tumor cells to mimic systemic 
or adjuvant therapy, and liver colonization was quantified (18, 31, 63). 
Quantification of visible macrometastases and histopathological 
analysis of serial sections through the liver showed that mice primed 
with FAKi alone or before gemcitabine/Abraxane, but not chemo-
therapy alone, had significantly fewer liver metastases than control 
conditions [Fig. 6B (macrometastases, quantified in Fig. 6C and 
confirmed in serial sections in Fig. 6, D and E)]. Furthermore, in 
line with our finding in the primary tumor (Fig. 5, B and C), live 
FUCCI imaging in the liver revealed that in control versus gemcitabine/
Abraxane conditions, any metastases that were formed were evident 
with a clear shift to S-G2-M phase of the cell cycle in the chemotherapy 
arm [Fig. 6, F and G (compare panel 1 versus 2, red-to-green shift), 
and movie S6]. In the FAKi-primed condition, however, both the 
size and number of metastases were reduced, and in those small 
metastases that remained, there was also a significant shift of cells to 
S-G2-M for FAKi priming alone and combination therapy at 
secondary sites for residual metastases [Fig. 6, F and G (compare 
panel 3 versus 4, red-to-green shift), and movie S6]. This therefore 
reveals a global or systemic benefit of FAKi priming in the adjuvant 
disease setting in addition to its effect at the locally invasive primary 
site. Furthermore, CD31 staining in liver metastases showed that 
FAKi priming alone or in combination with chemotherapy resulted 
in smaller, less mature vasculature within metastases (fig. S5, A and 
B), indicating that FAKi priming may also disrupt the formation of 
nascent vessels at secondary sites or indirectly affect metastatic 
establishment due to reduced vascularization, in line with the known 
role of FAK in angiogenesis (64, 65).
The reduced number of metastases observed here also led us to 
assess whether KPC cell survival in transit was affected by FAKi 
priming. We therefore initially exposed cancer cells to anchorage- 
independent growth (AIG; fig. S5C), where single KPC cells were 
suspended and grown in agarose to mimic anoikis during vascular 
transit, as previously achieved (18). Target validation using 
FLIM-FRET imaging of the FAK biosensor in these suspended cells 
revealed that FAK is also active in this 3D-detached setting, indicating 
that KPC cells could also be vulnerable to FAK inhibition in this 
context during transit [Fig. 6H (inset, showing FAK activity and 
response to FAKi treatment via FLIM-FRET imaging in suspension)]. 
Here, cells were initially treated with FAKi or vehicle over a 7-day 
period. Quantification of clusters revealed a significant decrease in 
clusters upon treatment with FAKi (fig. S5, C to E). We next 
exposed KPC cells treated with FAKi or vehicle in an AIG setting to 
subsequent gemcitabine/Abraxane for 72 hours (fig. S5F). Here, 
chemotherapy alone significantly reduced the number of clusters, 
which was further improved upon by priming with FAKi, again 
demonstrating a potential systemic advantage to FAKi priming in 
this highly aggressive and metastatic disease (Fig. 6, I and J).
In line with assessing FAKi priming under AIG conditions, we 
next used a shear stress model to mirror the physical forces and 
environmental stress that cancer cells may encounter while transiting 
in the vasculature (18, 66). To mimic flow-induced shear stress 
forces found in the vasculature, cells were subjected to shear stress 
at a rate of 100 l/s with a max of 2500 dyne/cm2, for 5 cycles, 
following pretreatment with FAKi or vehicle, as previously achieved 
(18, 66). After exposure to shear stress, cells were analyzed by flow 
cytometry for alterations in apoptosis via annexin V/propidium 
iodide (PI) staining and subjected to parallel testing of their post–
shear stress invasive capacity (Fig.  6K, flow chart). Critically, no 
significant difference in apoptosis was observed in cells pretreated 
with FAKi before shear stress (P0); however, in cells that had been 
exposed to shear stress (P5), we observed a significant increase in 
apoptosis under FAKi-primed conditions (Fig. 6, L and M). In 
parallel, cell invasion for 14 days after exposure to shear stress was 
also examined and revealed a further inhibition of invasion under 
FAKi-primed conditions (Fig. 6, N and O). This indicates that 
beyond inhibiting primary PC invasion (Fig. 3, M and N), FAKi 
priming also has the capacity to affect tumor cell survival during 
transit in the circulation, and in addition, for those cells that do 
survive shear stress in the circulation, their capacity to invade and 
colonize secondary tissue may also be impaired.
Patient-derived models reveal a potential to stratify patients 
for FAKi priming before chemotherapy in PDAC
PDAC has a highly heterogeneous molecular fingerprint, and inter-
tumoral variability is a known hurdle in the lagging improvement 
of current therapies and patient survival. IHC staining for both 
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Fig. 6. FAKi priming reduces metastasis and improves response to gemcitabine/Abraxane at secondary sites. (A) Timeline of KPC-FUCCI intrasplenic study. (B and 
C) Representative images (B) and quantification of visible liver metastases (C) upon priming with vehicle or FAKi followed by saline or gemcitabine/Abraxane. (D and 
E) Representative hematoxylin and eosin images (D) and quantification of liver metastases per square millimeter (E) (dotted lines). (F and G) Representative images (F) 
and quantification of FUCCI reporter (G) in KPC-FUCCI liver metastases. Scale bars, 50 m. n = 8 (vehicle/saline), n = 9 (vehicle/gemcitabine/Abraxane), n = 9 (FAKi/saline), 
and n = 10 animals (FAKi/gemcitabine/Abraxane), ≥6 FOVs per animal (G). (H) Representative images of day 7 KPC AIG clusters treated with vehicle or FAKi (scale bars, 100 m) 
with zoomed maps of ECFP fluorescence lifetime (scale bars, 50 m). (I and J) Representative images (I) and quantification of KPC AIG cluster number (J) (normalized to 
vehicle/gemcitabine/Abraxane) primed with vehicle or FAKi followed by saline or gemcitabine/Abraxane. Scale bars, 100 m. (K) Schematic representation of shear stress 
assay with KPC cells. (L and M) Quantification (L) and representative fluorescence-activated cell sorting (FACS) plots [annexin V/propidium iodide (PI)] (M) upon treatment 
with vehicle or FAKi and no shear stress (P0) or with shear stress (P5). (N and O) Representative images (N) and quantification of KPC invasion (O) treated with vehicle or 
FAKi before shear stress. Scale bars, 50 m. n = 3 (AIG and invasion) and n = 5 (FACS) biological repeats, 3 replicates per treatment group per repeat. Results: 
means ± SEM. P values were determined using a two-way ANOVA (G) and one-way ANOVA (C, E, J, L, and O) with Tukey correction for multiple comparisons. Unless otherwise 
stated, significance is compared to vehicle. ns, P > 0.05; *P < 0.05, **P < 0.01, and ***P < 0.001. FITC, fluorescein isothiocyanate.
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Fig. 7. A FAK signature reveals a graded response to stromal and epithelial FAKi priming before gemcitabine/Abraxane. (A) Schematic representation of PDAC 
PDX, PDCL, and PDX TMA establishment. (B) Representative images of TKCC05 and TKCC10 PDX TMA samples stained with total and pTyr397-FAK. Scale bars, 50 m; n = 3 
cores per PDX. (C) Quantification of pTyr397-FAK levels in PDCLs [mass spectrometry, top; data obtained from (67)] and confirmation via Western blot (bottom), highlighting 
TKCC05 (orange; low active, high total FAK) and TKCC10 (purple; high active, low total FAK) cells. (D to G) Representative images (D and F) and quantification (E and G) 
(normalized cell number at >200-m depth) of green fluorescent protein (GFP)–stained TKCC05 cells (D and E) and pan-cytokeratin–stained TKCC10 cells (F and G) invading 
into organotypic matrices primed with vehicle or FAKi (dotted line, 200-m invasion depth). Scale bars, 50 m. n = 3 biological repeats, 3 matrices per repeat, 3 FOVs per 
matrix. Results: means ± SEM. P values were determined using an ordinary one-way ANOVA with Tukey correction for multiple comparisons. Unless otherwise stated, all 
significance is compared to vehicle. (H) Timeline for TKCC05 and TKCC10 orthotopic studies. IVIS, In Vivo Imaging System. (I to L) Kaplan-Meier analysis of survival (I and 
K) and time to metastasis (J and L) in mice with TKCC05 (I and J) or TKCC10 (K and L) orthotopic tumors treated with vehicle/saline (TKCC05, n = 10; TKCC10, n = 8), vehicle/
gemcitabine/Abraxane (TKCC05, n = 9; TKCC10, n = 8), FAKi/saline (TKCC05, n = 8; TKCC10, n = 7), or FAKi/gemcitabine/Abraxane (TKCC05, n = 8; TKCC10, n = 8 animals). 
(M) Percentage of TKCC10 mice with visible liver metastases at endpoint. Kaplan-Meier curves were compared using log-rank Mantel-Cox test. ns, P > 0.05; *P < 0.05, 
**P < 0.01, and ***P < 0.001.
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active (pTyr397-FAK) and total FAK expression was performed on 
TMAs of patient-derived xenograft (PDX) tumors generated from 
the APGI cohort (Fig. 7, A and B) (18, 30–32). Grading for staining 
intensity and coverage (fig. S1C), along with analysis of PDCLs by 
phosphotyrosine-enriched mass spectrometry and Western blotting 
(Fig. 7C) (67), identified heterogeneous FAK activity and expression 
across the PDCL panel. From here, we identified TKCC10 as an 
example of “high–FAK activity, low–FAK expression” signature 
and TKCC05 as an example of “low FAK activity, high FAK expression” 
[Fig. 7, B and C (orange versus purple box)]. These FAK activity 
and expression status are maintained upon subsequent orthotopic 
injection of isolated PDCLs into the pancreas [compare fig. S6, A 
and B (PDX tumors), with fig. S6, C and D (matched PDCL tumors), 
respectively]. Expression and FLIM-FRET imaging of the FAK-FRET 
biosensor in both TKCC05 and TKCC10 cells confirmed that both 
PDCLs maintain their FAK activation status with TKCC05-FAK 
cells exhibiting low lifetimes, indicating a low basal level of FAK 
activity, while TKCC10-FAK cells showed a high lifetime, indicating 
high FAK activity (fig. S6E).
To evaluate the potential of transient stromal manipulation and 
epithelial treatment on a personalized basis, TKCC05 and TKCC10 cells 
were seeded onto contracted organotypic matrices as previously 
performed using KPC cells (Fig. 3, A to C). Analysis of personalized 
organotypic matrices revealed that while low–FAK activity, high 
FAK–expression TKCC05 patient-derived cells did not respond to 
late epithelial treatment, FAKi priming and disruption of the matrix 
significantly decreased TKCC05 invasion into the matrix, which 
was not improved upon by chronic treatment (Fig. 7, D and E). This 
was independent of changes in survival or cell proliferation of 
cancer cells within the matrices (fig. S6, F and G). Invasion in the 
high–FAK activity, low–FAK expression TKCC10 patient-derived 
cells was significantly reduced upon both epithelial (late) and stromal 
(early) FAK inhibition, which was also not improved upon in a 
chronic treatment setting (Fig. 7, F and G). Again, this effect was 
independent of changes in cancer cell survival or cell proliferation 
in this setting (fig. S6, H and I). These data suggest that maximal 
benefits of FAKi priming may be evident where both epithelial and 
stromal FAK activities are present, while others may only benefit 
from stromal intervention.
Hence, we sought to assess the long-term effect of FAKi priming 
on therapeutic response to gemcitabine/Abraxane, metastasis, and 
survival in orthotopic settings by injecting luciferase-expressing 
TKCC05 or TKCC10 cells into the pancreas of mice. Following 
visualization of established primary tumors by whole-body In Vivo 
Imaging System (IVIS) imaging of the luciferase signal (average flux 
of 5.5 × 108), mice were subjected to repeated cycles of FAKi priming 
for 3 days before gemcitabine/Abraxane treatment (see schematic 
in Fig. 7H). In the low–FAK activity, high–FAK expression TKCC05 
model, survival was improved upon treatment with gemcitabine/
Abraxane alone (Fig. 7I), and in line with our personalized organo-
typic invasion data (Fig. 7, D and E), time to metastasis was also 
increased in this setting (Fig. 7J). This reduction in metastatic 
progression, however, was not sufficient to significantly improve 
survival upon priming with FAKi alone or before chemotherapy 
(Fig. 7I and fig. S7). Conversely, treatment of high–FAK activity, 
low–FAK expression TKCC10 tumors with FAKi priming alone 
significantly improved survival compared to control [Fig. 7K and 
fig. S8; vehicle, saline (gray) mean survival: 62 days; FAKi, saline 
(blue) mean survival: 74 days]. Furthermore, FAKi priming before 
gemcitabine/Abraxane treatment also significantly improved survival 
compared to chemotherapy alone [Fig. 7K; vehicle, gemcitabine/
Abraxane (yellow) mean survival: 147 days; FAKi priming, gemcitabine/
Abraxane (green) mean survival: 163 days; fig. S8]. Time to metastasis 
was also significantly enhanced in this setting (Fig. 7L), and critically, 
in the FAKi combination arm with gemcitabine/Abraxane, the 
number of mice with macrometastases in the liver at endpoint was 
lowest (reduced to 50%; Fig. 7M) in addition to the significant 
survival advantage observed in those animals. Together, this graded 
response to FAKi priming before gemcitabine/Abraxane between 
TKCC05 and TKCC10 PDCLs highlights the need to identify valid 
biomarkers to guide combination treatment regimens in a person-
alized medicine approach to this highly heterogeneous disease, 
where the FAK activity status of patient tumors could be potentially 
used to identify patients who may benefit from FAKi priming 
before chemotherapy and recognize patients who may not respond 
to current clinical FAK-based targeted therapy in PC (19). In this 
way, our intravital assessment to dissect the benefits of FAK inhibition 
in PC could help guide future and ongoing clinical trials in this 
active arena of personalized medicine.
Analysis of reduced Merlin expression as a potential 
biomarker for FAKi sensitivity in PC
We next sought to establish a potential biomarker to stratify patients 
with PC for FAKi priming before chemotherapy. Merlin, the product 
of the neurofibromatosis type 2 (NF2) tumor suppressor gene, 
functions as a linker between transmembrane proteins and the actin 
cytoskeleton (22). It has recently been identified that in Merlin-high 
cells, stable cell-cell interactions decrease cell dependence on cell-
ECM signaling through FAK (20, 22). Conversely, Merlin-low cells 
rely on cell-ECM contacts, via integrin/FAK signaling, for their 
survival and proliferation, thus rendering them increasingly sensitive 
to FAK inhibition (20, 22). Given the graded response observed 
between the two different patient tumors from in vitro and in vivo 
settings, tumors from both PDX models and orthotopic injections 
of PDCLs were stained for Merlin. This revealed that Merlin expres-
sion in original TKCC10 PDX tumors was significantly lower than 
in TKCC05 tumors (Fig. 8, A and B), which was maintained when 
PDCLs generated from these PDXs were orthotopically reimplanted 
to establish palpable tumors in the pancreas (Fig.  8C). Together, 
this suggests that the observed differences in sensitivity to FAK 
inhibition between the pancreatic PDCLs may be associated with 
different levels of Merlin expression, where low Merlin expression 
may be linked to improved response to FAKi, in line with preclinical 
and clinical studies in other cancers (20, 21).
To investigate whether there is a causal relationship in PDAC 
between Merlin expression and cell response to FAKi, lentiviral 
short hairpin RNA (shRNA) targeting was used to reduce Merlin 
expression in the Merlin-high TKCC05 PDCL, which poorly 
responded to FAKi. We assessed stable pools of scrambled control 
and Merlin knockdown cells (henceforth pLKO.1, Merlin-48, and 
Merlin-95) to confirm Merlin knockdown (Fig. 8D and quantified 
in fig. S9A) and also show that Merlin knockdown did not alter 
FAK expression or activity [Fig. 8D and quantified in fig. S9 (B and 
C)]. Using AIG assays, where cells rely on cell-cell contact, we next 
assessed whether Merlin knockdown would sensitize cells in this 
setting to FAKi. A reduction in cell clusters in response to epithelial 
FAK inhibition was observed for Merlin-48 and Merlin-95 cells 
compared to pLKO.1 cells (Fig. 8, E and F, and fig. S9D), indicating 
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Fig. 8. Manipulation of Merlin can sensitize nonresponsive patient-derived tumors to FAKi before chemotherapy and induce disease stabilization. (A) Schematics 
of establishment of PDXs, PDCLs, and PDCL-generated orthotopic tumors. (B and C) Representative Merlin-stained images and quantification of TKCC05 (orange) and 
TKCC10 (purple) PDX (B) and PDCL-generated tumors (C). Scale bars, 50 m. (D) Western blot of pTyr397-FAK, total FAK, and Merlin in TKCC05 pLKO.1, Merlin-48, and 
Merlin-95 cells on CDMs treated with vehicle or FAKi. n = 3 repeats, 1 CDM per condition per repeat [quantified in fig. S9 (A to C.)]. GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase. (E and F) Representative images (E) and quantification of TKCC05 pLKO.1 and Merlin-48 AIG assays (F) treated with vehicle or FAKi. n = 3 repeats, 4 replicates 
per treatment group per repeat. (G) Timeline for TKCC05 pLKO.1 and Merlin-48 tumors. (H and I) Quantification of TKCC05 pLKO.1 (solid) and Merlin-48 (dashed lines) 
tumor growth over time (H) and tumor size at day 26 (I) upon treatment with vehicle/saline (pLKO.1, n = 9; Merlin-48, n = 9), vehicle/gemcitabine/Abraxane (pLKO.1, 
n = 10; Merlin-48, n = 9), FAKi/saline (pLKO.1, n = 9; Merlin-48, n = 10), and FAKi/gemcitabine/Abraxane (pLKO.1, n = 8; Merlin-48, n = 10 animals). (J) Representative images 
of endpoint tumors. Scale bar, 1 cm. (K) Quantification of TKCC05 pLKO.1 and Merlin-48 tumor growth rate upon treatment with FAKi/gemcitabine/Abraxane. Results: 
means ± SEM. (L) Kaplan-Meier analysis of human PC survival correlating to low Merlin and high FAK versus others. P values were determined using unpaired two-tailed 
t test with Welsh correction for unequal variance (B, C, and K), one-way ANOVA with Tukey correction for multiple comparisons (F, H, and I), or log-rank test (L). Unless 
otherwise stated, all significance is compared to vehicle. ns, P > 0.05; *P < 0.05, **P < 0.01, and ***P < 0.001.
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a potentially improved response to FAKi in Merlin-low patient 
PDAC cells. We therefore examined in vivo whether decreased 
Merlin expression now renders TKCC05 PDCLs more sensitive to 
FAKi in combination with gemcitabine/Abraxane. Following 
establishment of palpable tumors (see schematic in Fig. 8G), mice 
were cycled through treatment rounds of FAKi for 3 days before 
gemcitabine/Abraxane treatment, as previously achieved (Fig. 7H). 
While we observed no significant difference in subsequent tumor 
growth between control and Merlin knockdown tumors for vehicle 
and single-agent treatments, we now observed a significantly 
improved response to FAKi and gemcitabine/Abraxane combination 
treatment in Merlin knockdown TKCC05 (Merlin-48) tumors com-
pared to control (pLKO.1; Fig. 8, H to J, compare solid green line to 
dashed green line). This significantly enhanced response to FAKi 
priming and chemotherapy in Merlin knockdown tumors was also 
evident in representative tumors obtained 24 hours after the final 
chemotherapy cycle (Fig. 8J). Critically, in the Merlin knockdown 
setting, TKCC05 tumors failed to grow beyond the initial palpable 
stage upon combination treatment, resulting in stabilized disease 
[Fig. 8H, arrow, compare tumor volume between days 8 and 26 for 
dashed green line; Fig. 8K, pLKO.1 doubled in size (growth rate, 
2.33), whereas Merlin-48 displayed stable disease (growth rate, 
1.04)]. Last, these results are in line with analysis from patient data 
from the ICGC cohort (267 samples; Fig. 8L) in which low Merlin/
high FAK significantly co-correlate with low survival in patients 
with PDAC and may represent a subset of patients with poor 
outcome/prognosis that could substantially benefit from FAKi priming 
before chemotherapy (Fig. 8L).
DISCUSSION
Tumor-stroma cross-talk and mechanoreciprocity play a pivotal role 
in driving tumor establishment, growth, and metastasis (14, 16, 44). 
The characteristically dense desmoplastic stroma of PDAC is thought 
to promote tumor progression while hampering chemotherapeutic 
efficiency (3, 63). Despite this, recent studies on stromal targeting 
have yielded conflicting results where total stroma ablation was 
seen to enhance tumor growth (3, 7, 52). However, alternative studies 
have indicated that transient manipulation of the matrix may be a 
promising strategy to reduce aggressive disease while minimizing 
the potential caveats of chronic stromal targeting (9, 11, 15, 18, 26). 
The integrin-FAK signaling axis transmits signals bidirectionally, 
permitting cells to sense and respond to their adjacent extracellular 
environment, which can become essential for cancer progression 
when cancer cells have to rely on interactions with their surrounding 
stroma [see schematic in fig. S9 (E to G)] (12–14, 22). This study 
focused on short-term stromal and epithelial FAK inhibition, by (i) 
deconstructing transient stromal manipulation, which reduces 
inherent outside-in signaling and can render cells vulnerable to 
chemotherapy, while also (ii) evaluating direct targeting of epithelial 
FAK activity to interrupt intrinsic inside-out communication (14). 
Hence, streamlining short-term stromal and epithelial FAK targeting 
is shown to enhance chemotherapeutic efficiency, simultaneously 
having potential to reduce off-target effects often associated with 
long-term chronic combinatory treatment regimens, which may 
lead to undesirable drug interactions. For example, FAKi has 
previously been shown to inhibit the cytochrome P450 isoform 
CYP3A, which is the main metabolizing enzyme for taxane-based 
chemotherapeutics, such as Abraxane (37, 68). Simultaneous FAKi 
and Abraxane administration can therefore potentially lead to poor 
drug clearance and toxicity, warranting the temporal separation 
and sequential administration of these treatments.
A combination of 2D and 3D in  vitro techniques was used to 
deconstruct the benefits by which stromal and epithelial FAK inhibition 
may reduce PDAC aggressiveness in the context of gemcitabine/
Abraxane chemotherapy. These studies may help guide which 
patient subgroup in this highly heterogeneous disease is likely to 
respond best to FAKi priming in combination with chemotherapy. 
Similarly, interpatient variability and/or intratumoral heterogeneity 
and response from this study, including Merlin assessment before 
treatment, warrant future assessment for combination with gemcitabine/
Abraxane [see schematic in fig. S9 (E to H)] and other clinically 
relevant chemotherapy treatments. This may also include other 
combination applications in PC, such as the recent combination of 
FAKi with immunotherapy or mitogen-activated protein kinase 
kinase (MEK) inhibition in PC in which administration of multiple drug 
combinations and chronic treatment can serve as a bottleneck or a 
limitation for patient treatment in this disease (8, 15, 53, 69, 70). 
Moreover, our work also reveals that PDAC is susceptible to FAK 
inhibition during tumor transit and that FAKi priming has addi-
tional roles in enhancing PDAC apoptosis in response to shear 
stress and reducing subsequent post–shear stress invasion and 
colonization capacity in this setting (62, 66). This is in line with the 
clinical management of PC since a large proportion of patients 
present with locally invasive and metastatic disease, indicating 
applicability of our study to adjuvant therapy in aggressive and 
invasive PC cases.
Resistance to chemotherapy is often described as a result of 
dysregulated membrane transporters and metabolic enzymes in the 
epithelial compartment, but stromal-tumor feedback and mechano-
reciprocity between cells and their environment have also emerged 
as a key player in PC response to therapy (18, 43, 52, 54, 56, 71). Our 
results suggest that the biomechanics of the environment rather 
than direct or chronic FAK inhibition can lead to a shift in PDAC 
cell cycle distribution that may favor chemotherapeutic performance. 
Future studies may provide further insight into how biomechanics 
regulate chemosensitivity, for example, by causing an accumulation 
of cells in S-G2-M, increasing the time that cells spend in S-G2-M, 
and/or inducing an initial S-G2-M cell cycle arrest, which could all 
make cells vulnerable for subsequent S-G2-M–targeting chemo-
therapy (43, 72, 73). ECM proteins, such as laminin, collagen I, and 
fibronectin have previously been associated with intrinsic resistance 
to chemotherapy in multiple cancers, including PC (5, 56). Stromal 
targeting may reduce ECM content and biomechanics via blocking 
the de novo synthesis or cross-linking of ECM molecules or by 
increasing the production of ECM-degrading enzymes. We and 
others have previously shown that the Src/FAK signaling axis can 
regulate the secretion and activation of matrix metalloproteinases, 
which are known to proteolytically degrade ECM (29, 74, 75). This, 
in addition to reducing ongoing collagen cross-linking, could 
collectively contribute to the ECM reduction that we observe in vivo. 
Furthermore, recent work has demonstrated that targeting fibro-
blast contractility via Rho associated coiled-coil containing protein 
kinase (ROCK) inhibition significantly reduces cancer progression 
(17), and in particular, transient stromal priming via ROCK inhibi-
tion reduces ECM organization and stiffness and sensitizes PDAC 
cells to chemotherapy while also reducing their metastatic capacity 
(18). This is in line with similar studies whereby inhibition of collagen 
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cross-linking through Lysyl oxidase (LOX) inhibition in combination 
with gemcitabine impaired PDAC progression (6). In addition, 
reprogramming of the PDAC tumor stroma by long-term FAK 
inhibition leads to the acquisition of therapeutic resistance (53), 
suggesting that in a chronic treatment setting, resistance to stromal 
targeted therapies can emerge. These studies highlight the impor-
tance of the ECM in response to standard-of-care chemotherapy 
and provide a rationale for how short-term priming rather than 
chronic stromal treatment may be essential to maintain treatment du-
rability and enhance gemcitabine/Abraxane therapy. Notably, 
assessing surgical human PDAC samples from the APMA cohort, 
which have been treated presurgically with chemotherapy, readily 
demonstrated an increase in fibrosis upon neoadjuvant treatment, 
suggesting that stromal priming before treatment could also have 
clinical benefits in blunting this fibrotic reaction in PDAC.
Personalized medicine is an emerging treatment option in the 
clinical management of PDAC and could potentially improve upon 
traditional “one-size-fits-all” approaches. Here, individual tumors 
are treated on the basis of a defined phenotype and the identifica-
tion of predictive biomarkers of response to frequently used 
therapeutics (3, 20). Personalized therapy has offered progresses in 
patient survival outcomes in a number of cancer types (19). This 
highlights the critical need to rapidly identify and validate prognostic 
and predictive biomarkers for drug response in PC. Here, using 
intravital imaging in live tumors, we identified a graded response to 
transient epithelial and stromal FAK inhibition in reducing PDAC 
invasiveness and also rendering a subtype of patients with PC, with 
high FAK and low Merlin signature, exquisitely vulnerable to 
subsequent chemotherapy. In line with previous observations in 
patients with mesothelioma (20, 21), we reveal that Merlin status 
may also predict for FAKi sensitivity in PDAC, and on the basis of 
our preclinical data using patient-derived assessment, this may 
warrant further investigation. Molecular manipulation of Merlin in 
previously poorly responding TKCC05 PDCLs resulted in a signifi-
cant shift in response in vivo and induced stabilized disease in this 
aggressive model. These results are in line with data from patient 
samples from the ICGC, in which low Merlin/high FAK status 
co-correlate with poor patient survival in PC and may represent a 
subset of patients who could substantially benefit from FAKi priming 
with chemotherapy in a stratified manner. The identification of 
potential biomarkers for treatment response, such as Merlin, may 
therefore facilitate which patients with PDAC are most likely to 
benefit from short-term FAKi priming before chemotherapy and 
warrants future assessment in this disease. Collectively this work, 
demonstrates that short-term FAK inhibition improves chemothera-
peutic efficiency in a subset of patients with PDAC and may be used 
to guide ongoing clinical trials involving FAK targeting in this 
highly aggressive and metastatic cancer.
MATERIALS AND METHODS
Study design
This study assesses the potential of short-term transient manipulation 
of the stromal microenvironment via FAK inhibition before 
gemcitabine/Abraxane chemotherapy in PDAC. In vitro CDMs, 
organotypic matrices, and AIG assays were conducted in indepen-
dent biological triplicates with three technical replicates per repeat 
and treatment group. Mouse numbers used in in vivo experiments 
are outlined in the corresponding figure legends. For in vivo priming 
studies, treatment began when tumors were palpable and had an 
average volume of 30 mm3 or average IVIS flux of 5.5 × 108.
FLIM-FRET analysis of the FAK biosensor was conducted on 
50 cells per group in three independent biological repeats for in vitro 
experiments and 100 cells per mouse for in vivo experiments. For 
FUCCI cell cycle analysis, in vitro experiments used at least three 
fields of view (FOVs). In vivo analysis was performed on 15 regions 
of interest (ROIs) for subcutaneous tumors and up to 15 metastases 
where possible for intrasplenic injections.
FAK and Merlin expression was assessed via the analysis of 
mRNA expression from the ICGC datasets. mRNA expression was 
segregated into quartiles, and Kaplan-Meier curves were generated 
with the log-rank test used to determine significance. PC arrays 
from the APGI cohort were used to assess stromal collagen levels 
and phosphorylated FAK (pTyr397) via IHC in a cohort of 231 patients 
(158 deceased with complete datasets) with untreated and operable 
primary tumors who had undergone pancreatectomy. In deceased 
patients with low ECM levels (Picrosirius coverage), pTyr397-FAK 
levels were segregated into high and low groups and Kaplan-Meier 
curves were generated.
Unless otherwise stated in the corresponding figure legends, all 
IHC, SHG, GLCM, and Picrosirius red analyses were conducted on 
three representative ROIs in organotypic matrices and five ROIs for 
CDMs, subcutaneous xenografts, and intrasplenic experiments. 
Liver metastatic burden following intrasplenic injection was analyzed 
on serial sections. Study endpoints for in vivo experiments were in 
compliance with the Garvan/St. Vincent’s Animal Ethics Committee 
(13/17, 14/06, 16/13, 19/10, and 19/13) and the Australian code of 
practice for care and use of animals for scientific purposes.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (GraphPad 
Software Inc., CA) with statistical significance given as not significant 
(ns) P > 0.05, *P < 0.05, **P < 0.01, and ***P < 0.001. For mRNA 
expression analysis of the ICGC cohort, statistical tests were per-
formed using R (version 4.0.2). For data normalized to 1, a one-sample 
t test was performed. FUCCI cell cycle data analysis was assessed 
using a two-way analysis of variance (ANOVA) with Tukey correction 
for multiple comparisons. Kaplan-Meier curves were compared 
using a log-rank Mantel-Cox test. Unless otherwise stated, follow-
ing normality conformation, all other data were analyzed using an 
ordinary one-way ANOVA with a Tukey correction for multiple 
comparisons.
Animals
Animal experiments were conducted in accordance with the 
Garvan/St Vincent’s Animal Ethics Committee guidelines (13/17, 
14/06, 16/13, 19/10, and 19/13) and in compliance with the Australian 
code of practice for care and use of animals for scientific purposes. 
Mice were kept in individual ventilated, isolated cages on a 12-hour 
light/12-hour dark cycle and fed ab libitum.
Drug treatment schedules
Stock solutions of FAKi (PF-562271, SelleckChem) were prepared 
at 50 mM in dimethyl sulfoxide (DMSO) for in vitro utilization, 
while, for in vivo studies, FAKi was dissolved in DMSO and diluted 
in 20% (w/v) Gelucire 44/14 (Gattefosse, 3051) and sterile water to 
a final concentration of 5% FAKi/vehicle, 5% (w/v) Gelucire 44/14, 
and 90% sterile water. In vitro, FAKi was used at 250 nM and 1 M 
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concentrations in cell culture medium with DMSO as vehicle 
control. To assess chemotherapeutic response, gemcitabine (Jomar Life 
Research) and nab-paclitaxel (Abraxane, Specialised Therapeutics) 
were used at 100 nM each in tissue culture medium with saline as 
vehicle control.
In vivo, FAKi (PF-562271, SelleckChem) was administered twice 
daily by oral gavage for 3 days, using a 22-gauge feeding tube 
(Instech Laboratories, FTP-22-25) coated in 24% sucrose solution 
(Sigma-Aldrich, S9378). In subcutaneous models, treatment com-
menced 6 days after KPC cell injection when tumors had reached an 
average size of 30 mm3. For intrasplenic models, mice were subjected 
to three treatments with FAKi before and after intrasplenic injec-
tion of KPC cells. In pancreatic orthotopic models, FAKi treatment 
began when tumors were palpable and detectable by IVIS imaging 
(average flux of 5.5 × 108) around 1 week after intrapancreatic 
injection for TKCC05 cells and around 4 weeks for TKCC10 cells. 
Nab-paclitaxel (30 mg/kg; Abraxane, Specialised Therapeutics) and 
gemcitabine (70 mg/kg; Jomar Life Research) were dissolved in sterile 
saline and administered by intraperitoneal injection in a treatment 
schedule, as outlined in the corresponding figures and figure legends.
Cloning and generation of plasmids
The lipid raft/membrane–localized intramolecular Lyn-FAK FRET 
biosensor was provided by Y.W., University of California, Los 
Angeles (33). The Lyn-FAK biosensor was subcloned into the Gateway 
shuttle vector pENTR2b (Thermo Fisher Scientific, A10463) and 
amplified using competent Escherichia coli (DH5, Thermo Fisher 
Scientific) cells. The pENTR2b-Lyn-FAK construct was then sub-
cloned into the Gateway compatible PiggyBac transposon–based 
destination vector (pPBDEST51; Thermo Fisher Scientific, 12285011), 
by LR reaction using LR Clonase II as per the manufacturer’s 
instructions to generate pPBDEST-Lyn-FAK. All sequencing was 
performed in-house at the Garvan Molecular Genetics facility 
(Sydney, Australia) and verified using SnapGene (GSL Biotech: 
snapgene.com).
Cell culture
Primary 83,320 KPC cells have previously been isolated from 
end-stage Pdx1-Cre, LSL-KrasG12D/+, LSL-Trp53R172H/+ KPC mice 
(27, 29, 35). Telomerase-immortalized fibroblasts (TIFs) were also 
generated previously (18, 28, 76). KPC cells, TIFs, and human 
embryonic kidney (HEK) 239T cells were maintained in Dulbecco’s 
modified Eagle’s media (DMEM; high glucose, pyruvate; Gibco) 
supplemented with 10% fetal bovine serum (FBS; HyClone) and 
10 mM Hepes (Gibco). TKCC05 cells were maintained in media 
consisting of DMEM/Ham’s F12 media (Gibco) supplemented with 
7.5% FBS, 10 mM Hepes, 13.3 mM glucose, hydrocortisone (40 ng/ml), 
insulin (0.1 IU/ml), and human recombinant epidermal growth 
factor (EGF; 10 ng/ml). TKCC10 cells were maintained in 1:1 M199 
media/Ham’s F12 medium (Gibco) supplemented with 7.5% FBS, 
15 mM Hepes, 2 mM glutamine, 1× MEM vitamins, apotransferrin 
(25 ng/ml), insulin (0.2 IU/ml), 6.5 mM glucose, hydrocortisone 
(40 ng/ml), EGF (20 ng/ml), triiodothyronine (0.5 pg/ml), and 
O-phosphoryl ethanolamine (2 g/ml). All cells were cultured in 
the presence of penicillin-streptomycin (100 U/ml and 100 mg/ml, 
respectively) and maintained at 37°C and 5% CO2. Experiments 
were conducted at 20% oxygen in a Heracell 150i CO2/O2 incubator 
for KPC, TIF, and TKCC05 cell lines and at 5% oxygen for TKCC10 
lines. All cell lines were mycoplasma-free.
Generation of stable cell lines
Generation of stable cell lines expressing the pPBDEST-Lyn-FAK 
biosensor was achieved by cotransfection of the pPBDEST-Lyn-FAK 
vector and pCMV-hyPBase (obtained from the Wellcome Trust 
Sanger Institute) (77) using Lipofectamine 3000 Reagent as per the 
manufacturer’s instructions. Positive cells were selected by fluorescence- 
activated cell sorting (FACS). Cancer cells were engineered to express 
the FUCCI cell cycle reporter (mKO2-hCdt1 and mAG-hGeminin) 
(31), Luciferase-GFP (green fluorescent protein; pLV430G), and 
pLKO.1 or Merlin targeting shRNA using a third generation lenti-
viral packaging system. Lentiviral particles were generated using 
HEK293T cells. Briefly, cells were treated with the transfection 
mixture containing pMDLg/pRRE (Addgene, plasmid 12251), pRSV-
Rev (Addgene, plasmid 12253), pMD2.g (Addgene, plasmid 12259), 
plasmid DNA, and Lipofectamine 3000, as per the manufacturer’s 
protocol, and the medium was replenished after 24 hours. Lentiviral 
particles were harvested by filtration through a 45-m filter. KPC, 
TKCC05, and TKCC10 cells were transduced with lentiviral dilutions 
for 48 hours in the presence of Polybrene (8 g/ml) and washed, 
and stable positive cells were then selected using FACS (fluorescent 
constructs) or puromycin (2 g/ml; p.LKO.1 and Merlin shRNA).
AIG assays
AIG assays were performed as previously described (18). Briefly, 
2 ml of cell-free 1% Low Melting Point Agarose (Quantum Scientific) 
was added to the base of six-well plates and allowed to solidify at 
room temperature for 1 hour. KPC cells were trypsinized, filtered 
(40-m cell strainer), and diluted to obtain a single-cell suspension 
at 1000 cells/ml. Five hundred microliters of this cell suspension 
was then mixed with 1 ml of 0.3% agarose and plated over the 
solidified 1% agarose layer. The mixture was allowed to set at room 
temperature for 30 min and imaged to validate the absence of cell 
clusters. Cell clusters arising from single cells were allowed to grow 
in the presence of vehicle or FAKi for 7 days for monotherapy. For 
combination therapy, cells were treated with vehicle or FAKi until 
day 6, followed by the addition of 100 nM gemcitabine and 100 nM 
Abraxane for an additional 72 hours. Images for analysis of cluster 
size were acquired on a DM4000 Leica microscope, and the size was 
then measured on ImageJ (see the “AIG cluster size” section in 
“Macros”). To analyze total cell cluster number, assays were stained 
with Quick Dip and imaged using a Leica MZ12.5 microscope to 
obtain images of the entire well and quantified in ImageJ.
CDM assays
CDMs were established as previously described using TIFs 
(18, 28, 36, 76). To generate CDMs on glass, the surface was coated 
with 2% gelatin and allowed to set at 37°C for 2 hours then rinsed 
twice with Dulbecco’s phosphate-buffered saline (PBS) and formalin- 
fixed at room temperature for 30 min. After two rinses with PBS, 
fixed gelatin cross-links were quenched in 1 M sterile glycine for 
30 min at room temperature, and coated plates were rinsed twice 
with PBS and once with DMEM before TIF cell seeding. TIFs were 
allowed to expand until confluent. Medium containing ascorbic 
acid (50 mg/ml) was then refreshed every other day for 7 days. For 
FAK inhibition, FAKi was added to the media at day 1 and refreshed 
on day 4. TIFs were removed at day 7 [extraction buffer: 0.5% (v/v) 
Triton X-100, 20 mM ammonium hydroxide, and 1% (w/v) sodium 
deoxycholate], and CDMs were rinsed with PBS before SHG imaging, 
seeding of cancer cells, or staining with Picrosirius red. After 
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removal of the fibroblasts, 2 × 104 KPC cells were seeded on the 
CDMs and allowed to adhere. For migration assays, KPC cells were 
allowed to adhere to the matrices for 8 hours before the addition of 
FAKi and subsequent live cell imaging for 8 hours. Tracking and 
quantification of cell migration were performed on binary images 
using a MATLAB plugin (CellTracker) (78). Representative tracks 
were plotted using MATLAB (MathWorks, USA). Cell streaming 
was monitored for 72 hours after KPC cell adhesion to the CDMs 
on an Incucyte. Images of matrix anisotropy and collective cell 
streaming were equally segmented into nine areas, and anisotropy 
(as a measure of coordinated migration) was quantified using the 
ImageJ plugin FibrilTool (42). Matrix fibrillar organization was 




Collagen I was extracted from rat tails as previously described 
(18, 26). Briefly, frozen rat tails were thawed, and collagen tendons 
were pulled free of the epithelium and skeletal structure using 
three-pronged tweezers. Extracted tendons from 10 to 12 tails were 
then solubilized in 1500 ml of 0.5 M acetic acid for 48 hours at 4°C 
on a magnetic stirrer. The mixture was then filtered through a 
strainer to remove sheath and insolubilized tendons before precipi-
tation with 10% (w/v) sodium chloride on a magnetic stirrer over 6 
to 8 hours. Once a homogenous opaque white solution was formed, 
the mixture was centrifuged at 10,000 rpm for 30 min at 4°C. The 
collagen precipitate was then dissolved in 400 to 600 ml of 0.25 M 
acetic acid overnight at 4°C on a magnetic stirrer, and the solution 
was then dialyzed in 4 liters of 17.4 mM acetic acid.
Contraction assays
Organotypic matrices were generated as described in (18, 26). Briefly, 
8 × 104 TIFs per matrix were embedded in a sodium hydroxide–
neutralized preparation of acid-extracted rat tail collagen (~2.5 mg/ml) 
in the presence of 1× MEM and 8.8% FBS. Matrices were allowed to 
set at 37°C before being detached and allowed to contract for 
12 days in DMEM with 10% FBS, 10 mM Hepes, and penicillin- 
streptomycin (100 U/ml and 100 mg/ml, respectively). For early 
treatment (priming), matrices were treated during contraction with 
vehicle or 250 nM or 1 M FAKi at day 0 and refreshed at day 6.
Invasion assays
After 12 days of contraction, TIF-contracted matrices were seeded 
with 1 × 105 KPC cells, 1 × 105 TKCC05 cells, or 1.5 × 105 TKCC10 
cells. After 72 hours of cancer cell growth, seeded matrices were 
moved to an air-liquid interface on a metal grid, and cancer cells 
were allowed to invade into the matrix for 14 days for KPC cells and 
for 21 days for TKCC05 and TKCC10 cells. For late treatment 
regimes, medium was supplemented with vehicle, 250 nM FAKi, or 
1 M FAKi and refreshed three times per week during cell invasion. 
Chronic treatment involved FAKi treatment during both matrix 
contraction and invasion. To assess chemotherapeutic response, 
100 nM gemcitabine and 100 nM Abraxane were added for the final 
72 hours of invasion. Matrices were then fixed in 10% neutral 
buffered formalin and processed for paraffin block embedding, 
sectioning, and histological and IHC analysis (Garvan Histopathology 
Facility). For KPC-FAK and KPC-FUCCI imaging of invasion into 
organotypic matrices, matrices were imaged before fixation. Using 
cell numbers calculated from pan-cytokeratin staining for KPC 
and TKCC10 cells and anti-GFP staining for TKCC05 cells, cell 
invasion index was calculated as the total number of cells invad-
ing greater than 200-m depth divided by the cells on top of the 
matrix and normalized to the average invasion index of vehicle cells
  Invasive index =  
Number of cells > 200 μm depth
   ────────────────────  Cells on top of the matrix 
Fluid shear stress assays
KPC cells were cultured in the presence of vehicle or FAKi (250 nM 
and 1 M, refreshed every 24 hours) for 72 hours before being 
subjected to shear stress as previously described (18, 66). Briefly, cells 
were trypsinized and filtered to generate a single-cell suspension 
and resuspended at a concentration of 5 × 105 cells/ml in DMEM, 
and an aliquot designated as “P0” was isolated, which was not 
exposed to shear stress. The remaining cell suspension, “P5,” was 
exposed to five manual repeated passages of shear stress through a 
30-gauge needle at a constant flow rate of 100 l/s. Here, Poiseuille’s 
equation was used to measure shear stress, max = 4Q/R3, whereby 
Q is the flow rate (0.1 cm3/s),  is the dynamic fluid viscosity of the 
cell culture medium at room temperature (0.78 × 10−3 N•s/m2), and 
R is the radius of the needle (R = 7.94 × 10−3 cm), resulting in 
max = 2500 dyne/cm2 (66). After exposure to shear stress, 5 × 105 
cells were seeded into tissue culture flasks and used to assess cell 
death 24 hours after shear stress by flow cytometry using annexin V 
and PI staining. P0 and P5 cells (1 × 105) were seeded onto TIF- 
contracted matrices and allowed to adhere for 4 days before being 
moved to an air-liquid interface for 14-day invasions with untreated 
media refreshed three times weekly.
Fluorescence-activated cell sorting
FACS of cells was performed using the FACSCanto II (Becton 
Dickinson Biosciences) for annexin V/PI staining. For isolation of 
stable cell lines, a FACSAria III (Becton Dickinson Biosciences) was 
used. All quantifications were performed in FlowJo software (Tree 
Star Inc.).
Transfected cells were expanded and resuspended at 1 × 106 cells/ml. 
For isolation of pbDEST-Lyn-FAK–transfected cells, yellow fluo-
rescent protein–positive cells within a similar fluorescent range were 
selected. To obtain FUCCI-transfected stable cells, cells transfected 
with mKO2-Cdt1 (YG582/15-A) with a similar fluorescent range were 
selected. Following a further transfection with mAG- hGeminin 
(B530/30-A), again, cells with a similar fluorescent range were selected.
To analyze cell death following exposure to shear stress, an 
annexin V (fluorescein isothiocyanate)/PI staining kit was used on 
unfixed cells as per the manufacturer’s instructions. Quantification 
was performed in FlowJo software (Tree Star Inc.). A minimum of 
50,000 events were analyzed per sample.
ICGC, APGI, and APMA patient data
FAK and Merlin expression was assessed via the analysis of mRNA 
expression from the ICGC microarray datasets. mRNA expression 
was segregated into quartiles, and Kaplan-Meier curves were 
generated with the log-rank test used to determine significance. 
Statistical tests were performed using R version 4.0.2. For IHC 
analysis of patient TMAs from the APGI cohort, tumor cores of 
deceased patients (three per patient) with complete survival datasets 
(total, 158) were scored for stromal intensity (Picrosirius red) and 
segregated into low and high. Within the low–Picrosirius red 
cohort of patients, the stroma was then assessed for pTyr397-FAK 
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intensity and further segregated into high and low. Kaplan-Meier 
curves were generated, and a log-rank test was performed to deter-
mine significance. For analysis of APMA patient samples, surgical 
samples from n = 3 treatment-naïve patients and n = 4 neoadjuvant 
gemcitabine/Abraxane-treated patients were analyzed for Picrosirius 
red coverage (n = 5 FOVs per tumor).
Pillar plates
Multiwell array pillar plate slides were fabricated from poly(methyl 
methacrylate) as previously performed by the laboratory of N.G. 
(58, 59). Pillar stiffness ranges from 9 kPa (height, 27 nm) to 93 kPa 
(height, 205 nm) (58, 59). Individual pillars are 100 nm in diameter 
and spaced 300 nm apart and of varying height to obtain surfaces of 
different stiffness. KPC-FUCCI cells (2 × 103) were seeded onto 
pillar plates and allowed to adhere and proliferate for 72 hours 
before being imaged using confocal microscopy.
Polyacrylamide hydrogels
Polyacrylamide hydrogels with defined mechanical properties were 
prepared as previously described (15, 60, 61). Briefly, polyacrylamide 
solutions (3% acrylamide/0.1% bis-acrylamide for soft conditions 
and 6% acrylamide/0.1% bis-acrylamide for stiff conditions, with 
stiffness confirmed by bulk unconfined compression) were pre-
pared in PBS and degassed for 5 min to remove all oxygen. Before 
gel formation, coverslips were functionalized, to permit robust 
hydrogel attachment, for 5 min in functionalization solution [3% 
acetic acid and 0.5% 3-(trimethoxysilyl)propyl methacrylate in 
absolute ethanol]. Glass slides were treated with dichlorodimethylsilane 
to create a hydrophobic surface and easy hydrogel detachment 
following the completion of gelation.
Hydrogel gelation kinetics were initiated by adding 0.1% (w/v) 
freshly made ammonium persulfate and 0.1% tetramethyl- 
ethylenediamine. Hydrogel solution (100 l) was added to the glass 
side and sandwiched between the functionalized coverslip and 
hydrophobic glass slide. The gels were allowed to set for half an 
hour before careful removal from the dichlorodimethylsilane-treated 
glass slide. Bulk unconfined compression analysis was used to 
quantify the stiffness of hydrogels at 2 kPa (soft) and 20 kPa (stiff) 
(15). All gels were thoroughly washed with PBS overnight and 
stored at 4°C until further use. To enable cell attachment, gels were 
functionalized with rat tail collagen. For this, gels were washed 
three times with 50 mM Hepes buffer (pH 8.5), followed by incuba-
tion with sulfo-SANPAH (0.2 mg/ml) in 50 mM Hepes. The sulfo-
SANPAH was then activated with ultraviolet (UV) light at 365 nm 
for 10 min using a UV cross-linker box. The gels were then washed 
twice for 5 min with 50 mM Hepes and incubated overnight at 4°C 
with rat tail collagen (0.08 mg/ml; diluted in 17.4 mM acetic acid). 
Last, after three 5-min washes with PBS, the gels were sterilized 
under UV light for 20 min before cell seeding. Here, 5 × 103 KPC- 
FUCCI cells were seeded onto sterilized gels and allowed to adhere 
and proliferate for 24 hours before treatment with vehicle or FAKi 
(250 nM or 1 M) for 48 hours, followed by washout and treatment 
with 100 nM gemcitabine and 100 nM Abraxane for 24 hours. 
KPC-FUCCI cells were then imaged by confocal microscopy.
Scratch wound assay
For polarization assays, 1.5 × 105 KPC cells were seeded onto glass 
coverslips and grown until confluency. Monolayers were then 
wounded with a pipette tip and washed twice with PBS. Wounds 
were allowed to close over 2 hours in the presence of vehicle or 
FAKi (250 nM or 1 M) before fixation in 4% paraformaldehyde, 
and immunofluorescence staining of GM-130 was performed.
Intrasplenic injections
KPC-FUCCI cells (5 × 105 cells in 50 l of PBS) were injected into 
the spleen of BALB/c-Fox1nuAusb mice [anesthetized with 3% 
isoflurane, O2 (1 liter/min), with continuous vacuum to remove 
excess isoflurane] as previously described (18). Briefly, a left subcostal 
incision was made through the skin and the peritoneum exposing 
the spleen, into which tumor cells were injected using a 29-gauge 
needle. The injection site on the spleen was then sealed with 
cyanoacrylate, and the peritoneal wall and skin were individually 
sutured while treating topically with analgesia (Bupivicaine). Mice 
were subjected to three treatments with FAKi (10 mg/kg) or vehicle by 
oral gavage before intrasplenic injection, followed by three subsequent 
treatments. Furthermore, mice were treated with gemcitabine 
(70 mg/kg) and Abraxane (30 mg/kg) or saline on days 7, 8, and 
9 after injection, as previously performed (18). On day 10 mice, were 
euthanized for counting of visible metastasis and for imaging of liver 
metastases. Fresh organs were harvested and immediately imaged at 
37°C on a heated stage (maximum duration of 1 hour after euthanasia). 
Imaging of the FUCCI cell cycle reporter was performed by multi-
photon microscopy. Following imaging of liver metastases, livers 
were fixed in formalin for histological processing.
Subcutaneous injections and intravital imaging
KPC-FAK cells, KPC-FUCCI cells, TKCC05 pLKO.1 cells, or 
TKCC05 Merlin-48 cells were injected into the rear flank of 
BALB/c-Fox1nuAusb mice while under anesthesia [3% isoflurane, 
O2 (1 liter/min), with continuous vacuum to remove excess 
isoflurane]. KPC cells were injected at 1 × 106 in 50 l of PBS, and 
TKCC05 cells were injected at 2 × 106 in 80 l of PBS/Matrigel (1:1). 
Tumors were allowed to develop for 6 days to an average volume of 
30 mm3 for KPC tumors before treatment schedules commenced. 
For KPC-FAK–derived tumors, mice were treated with FAKi 
(10 mg/kg) or vehicle twice daily for 3 days with the final treatment 
2 hours before skin flap surgery and subsequent intravital imaging. 
For KPC-FUCCI–derived tumors, mice were treated with FAKi 
(10 mg/kg) or vehicle twice daily for 3 days (6:00 p.m. and 7:00, 
8:00, and 9:00 a.m.) before a single treatment with gemcitabine 
(70 mg/kg) and Abraxane (30 mg/kg) or saline on day 11, 24 hours 
before skin flap surgery and subsequent imaging. Mice were termi-
nally anaesthetized using a mix of xylazine (10 mg/kg) and Zoletil 
(50 mg/kg) and with additional maintenance of anesthesia using 3% 
isoflurane, O2 (1 liter/min), with continuous vacuum to remove 
excess isoflurane. Subcutaneous tumors were surgically exposed by 
a small incision around the tumor, which was further expanded 
using blunt dissection to separate the epidermis and dermis from 
the peritoneal wall, thereby creating a skin flap. The skin flap was 
expanded to a distance from the body suitable for imaging. Once 
the tumors were surgically exposed, imaging was performed with 
mice restrained on a heated stage at 37°C and maintained under 
anesthesia, for a maximum of 40 min. Following imaging, tumors 
were harvested and formalin-fixed for histological processing.
Orthotopic injections
For orthotopic survival experiments, NOD.Cg-PrkdcscidIL2rgtm1Wjl/
SzAusb mice were anesthetized [3% isoflurane, O2 (1 liter/min), with 
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continuous vacuum to remove excess isoflurane] and TKCC05-Luc 
[1.5 × 104 in 50 l of PBS/Matrigel (1:1)] or TKCC10-Luc [1 × 106 
in 50 l of PBS/Matrigel (1:1)] was injected into the pancreas during 
open laparotomy. Briefly, a left subcostal incision was made through 
the skin and peritoneum, exposing the pancreas, into which tumor 
cells were injected using a 29-gauge needle. The peritoneal wall and 
skin were then individually sutured using Vicryl resorbable sutures 
and clipped. For analgesia, mice were treated subcutaneously 
generally with buprenorphine (0.075 mg/kg) and topically with 
Bupivicaine (5 mg/kg). Treatment started when tumors were both 
palpable and visible by IVIS monitoring (average flux, 5.5 × 108). 
Treatment schedules began with twice daily oral gavage of FAKi 
(10 mg/kg) or vehicle for days 1, 2, and 3. Gemcitabine (70 mg/kg) 
and Abraxane (30 mg/kg) or saline were administered by intraperi-
toneal injection on days 6 and 9. After a further 3 days without any 
treatment, the treatment cycle recommenced. Tumor growth was 
monitored using IVIS imaging. Experimental endpoint was deter-
mined upon development of ascites, overnight weight loss of ≥10% 
or weight loss of ≥20% over the entirety of the experiment, hunching 
posture, or signs of pain. At endpoint, animals were euthanized; the 
pancreatic tumor, liver, lungs, and spleen were harvested; visible 
metastases were quantified; and tissues were formalin-fixed for 
histological processing.
Immunoblot
Cell were rinsed twice in PBS, and lysates were prepared in radio-
immunoprecipitation assay protein lysis buffer [50 mM Hepes, 
1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 0.5 mM 
EDTA, 50 mM NaF, 10 mM NA3VO4, and 1× protease inhibitor 
cocktail (Roche)]. Protein concentration was determined by 
Bradford assay, and the lysate volumes were adjusted accordingly 
to a final concentration of 1 g/l. Protein separation was performed 
by gel electrophoresis using 4 to 12% or 10% bis-tris protein gels. 
Separated proteins were transferred onto polyvinylidene difluoride 
membranes, which were blocked overnight at 4°C in 5% skim milk 
dissolved in tris-buffered saline (TBS) and 0.1% Tween 20 (TBST). 
After rinsing with TBST, membranes were incubated overnight at 
4°C in primary antibody solutions [TBS/bovine serum albumin 
(BSA)]. Antibodies and their respective dilutions are provided in 
Table 1. After rinsing with TBST, membranes were then incubated 
with horseradish peroxidase (HRP)–linked secondary antibodies 
(1:5000; diluted in 1% skim milk/TBST; GE Healthcare Limited), 
for 2 hours at room temperature, and rinsed with TBST. Ultra– 
enhanced chemiluminescence (ECL) or ECL reagent was used to 
visualize HRP signal imaged on a FUSION FX (Vilber) or on x-ray film 
(Fujifilm). Densitometry analysis of protein signal was performed 
in ImageJ (National Institutes of Health).
Histology, IHC, and immunofluorescence
Organotypic matrices and tumor tissues were fixed in 10% neutral 
buffered formalin, dehydrated using a graded series of ethanol, and 
embedded in paraffin. Paraffin sections were cut at a thickness of 
4 m and incubated at 60°C to maximize adhesion to Superfrost 
Plus slides. Cut sections were deparaffinized in xylene and rehydrated 
in ethanol (100 to 70%) washes. For hematoxylin and eosin stain-
ing, slides were stained on a Leica Autostainer XL. All IHC stains 
were performed on the Leica BOND RX or the DAKO. All optimi-
zation was performed using rabbit (Cell Signaling Technology, 
3900s) or mouse (DAKO, X0931) immunoglobulin G (IgG) controls.
For Picrosirius red staining, the sections were dewaxed in xylene 
and rehydrated in graded ethanol washes. Following hematoxylin 
counterstaining, sections were stained with 0.02% phosphomolybdic 
acid and 0.1% Picrosirius red (Polysciences) for fibrillar collagen. 
Sections were then rinsed in acidified water and dehydrated in 
graded ethanol before coverslipping. Slides were scanned using an 
Aperio slide scanner. For tumor sections, analysis of Picrosirius red 
coverage was analyzed using ImageJ (see the “Picrosirius red coverage” 
section in Macros), while an in-house MATLAB (MathWorks, 
USA) script was used to analyze the intensity and coverage of 
Picrosirius red–stained organotypic matrices.
For IHC on the Leica BOND RX, organotypic matrices and 
tumors sections were dewaxed using BOND Dewax Solution (Leica, 
AR2992) on a Leica BOND RX, followed by heat-induced epitope 
retrieval at 93°C for organotypic matrices and at 100°C for tumor 
sections, with epitope retrieval solution 2 (pH 9; Leica, AR9640) for 
30 min. The details for primary antibody dilution and incubation 
time are provided in Table 2. IHC staining was carried out on the 
Leica BOND RX Autostainer, followed by hematoxylin counter-
staining on a Leica Autostainer XL and coverslipping on a Leica 
coverslipper (CV5030). Samples were scanned using an Aperio 
slide scanner. For KPC tumors, 3,3′-Diaminobenzidine (DAB) coverage 
of tumor tissue was analyzed using ImageJ (see the “DAB coverage” 
section in Macros). CC3- and Ki67-stained organotypic matrices were 
scored manually for positive and negative cells, while tumor sections 
were analyzed for positive and negative cells using QuPath (79).
For staining on the DAKO, sections were deparaffinized in 
xylene and rehydrated in graded ethanol washes. Antigen retrieval 
was performed using citrate retrieval solution (pH 6; S1699, DAKO) 
under pressure at 125°C for 1 min, followed by 30 s at 95°C. Cooled 
slides were then transferred to a DAKO Autostainer, and IHC staining 
was performed using the antibodies listed in Table 3 using reagents 
from the DAKO EnVision system according to the manufacturer’s 
instructions. Samples were scanned using an Aperio slide scanner, 
and analysis of DAB coverage of tumor tissue was performed using 
QuPath (79).
For immunofluorescence staining of cell polarization assays 
(scratch wound), paraformaldehyde-fixed cells on glass coverslips 
were rinsed twice with PBS and incubated in blocking buffer 
[2.5% BSA (Sigma-Aldrich, A7906), 10% donkey serum (Jackson 
ImmunoResearch, 017-000-121), and 0.02% glycine (Sigma-Aldrich, 
G7126)] for 1 hour at room temperature. Cells were then incubated 
overnight at 4°C in anti–GM-130 (BD Transduction Laboratories, 
610823) primary antibody at 1:100 dilution. Cells were rinsed three 
Table 1. Primary antibodies used for immunoblotting.  
Antibody Company Product Dilution
Total FAK BD Biosciences 610088 1:500
pTyr397-FAK Invitrogen 44-625G 1:500
GAPDH (14C10) Cell Signaling 
Technology 2118L 1:40,000
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times in PBS and incubated in Alexa Fluor 488–coupled anti-mouse 
IgG secondary antibody and tetramethyl rhodamine isothiocyanate 
(TRITC)–phalloidin at 1:50 (Sigma-Aldrich, P1951) for 2 hours at 
room temperature. Cells were then rinsed twice with PBS, and 
nuclei were stained with DAPI (4′,6-diamidino-2-phenylindole; 
Sigma-Aldrich, D9542) at 1 g/ml for 15 min, followed by three PBS 
washes and coverslipping using VECTASHIELD microscope 
mounting medium (Vector Laboratories, H-1000). Imaging of 
GM-130 and phalloidin was performed using confocal microscopy.
Dual immunofluorescence staining was performed on 4-m 
Formalin-fixed paraffin-embedded (FFPE) KPC tissue sections. Slides 
were deparaffinized in xylene and rehydrated in graded ethanol washes 
before antigen retrieval using citrate retrieval solution (pH 6; DAKO, 
S1699) under pressure at 125°C for 1 min, followed by 30 s at 95°C. 
Cooled slides were then blocked for 1 hour at room temperature in 
PBS containing 3% BSA and 5% goat serum. Slides were incubated 
with primary antibodies diluted in blocking buffer: pTyr397-FAK (1:100; 
Abcam, ab39967), SMA (1:500; Abcam, ab21027), and E-cadherin 
(1:100; BD Biosciences, 610181). Secondary antibody staining (1:500; 
Jackson Immuno Research) was performed for 1 hour at room tempera-
ture in blocking buffer, followed by nuclear counterstaining with DAPI 
(1 g/ml; Sigma-Aldrich, D9542) in PBS. Samples were coverslipped 
with ProLong Diamond Antifade Mountant (Thermo Fisher Scientific).
Imaging techniques and data analysis in vitro and in vivo
Polarized light imaging of Picrosirius red staining
Polarized light microscopy was performed on fixed, deparaffinized, 
and rehydrated 4-m sections stained with 0.1% Picrosirius red 
(Polysciences, 29401-250). Polarized light signal of fibrillar collagen 
was taken using an Olympus U-Pot polarizer and an Olympus 
U-ANT transmitted light analyzer fitted to a DM4000 microscope 
(Leica). Quantification of birefringent signal was analyzed using 
ImageJ. Briefly, hue-saturation balance thresholding was applied 
(high birefringence/red-orange 0>H<29 | 0>S<255 | 70>B<255, 
medium birefringence/yellow 30>H<44 | 0>S<255 | 70>B<255, and 
low birefringence/green 45>H<245 | 0>S<255 | 70>B<255). Relative 
area of fibers was then calculated as percentage of total fibers 
(0>H<245 | 0>S<255 | 70>B<255).
SHG imaging
SHG imaging was performed on an inverted Leica DMS 6000 SP8 
confocal microscope with a Titanium-Sapphire femtosecond laser 
(Coherent Chameleon Ultra II) excitation source, operating at 
80 MHz and tuned to a wavelength of 880 or 920 nm. SHG intensity 
was recorded on an RLD-HyD at 440/20 or 460/50 nm, respectively. 
For organotypic matrices and CDMs, three representative FOVs 
(512 pixels × 512 pixels) were imaged over a 3D z-stack (80-m 
depth with a 2.52-m step size and 30-m depth with a 1.26-m step 
size, respectively). For tissue sections, five ROIs of deparaffinized 
and rehydrated 4-m unstained sections were imaged with a step 
size of 1.26 m and 20-m depth. SHG signal intensity and GLCM 
correlation were quantified using MATLAB (MathWorks, USA).
FUCCI cell cycle reporter imaging
Imaging of the FUCCI cell cycle reporter on pillar plates and on 
soft/stiff hydrogels was performed on an inverted Leica DMS 6000 
SP8 confocal microscope with a 25× 0.95 numerical aperture (NA) 
water objective. FUCCI was excited with a tunable argon laser at 
488 and 514 nm. Fluorescence emission was detected on internal 
HyDs at 520 to 545 nm and 570 to 600 nm for mAzami Green and 
mKusabira Orange, respectively. For organotypic matrices, pillar 
plates, and hydrogels, three ROIs (512 pixels × 512 pixels) were 
imaged over a 20-m z-stack with a step size of 2.52 m. Imaging of 
the FUCCI cell cycle reporter in tissues was performed on an 
inverted Leica DMS 6000 SP8 confocal microscope with a Titanium- 
Sapphire femtosecond laser (Coherent Chameleon Ultra II) and a 
25× 0.95 NA water objective with the excitation source tuned to a 
wavelength of 920  nm. The signal was recorded using RLD-HyD 
detectors (using band-pass emission filters at 460/50 nm for SHG 
signal, 525/50 nm for mAzami Green, and 585/40 nm for mKus-
abira Orange). Ten ROIs (512 pixels × 512 pixels) per tumors and 
15 ROIs (512 pixels × 512 pixels) per liver were imaged over a 20-
m z-stack with a step size of 2.52 m. 3D maximum projections 
were then generated using Leica LAS X software and analyzed 
using ImageJ to quantify percentage of red, green, and yellow 
nuclei indicative of G1-G0, S-G2-M, or G1-S cell cycle phase, 
respectively.
Imaging of cell polarization assays
Imaging of cell polarization assays was performed on a Leica DMI 
6000 SP8 Basic Confocal, using 488 and 514 nm for Alexa Fluor 488 
Table 2. Primary antibodies used for IHC, with staining performed on the Leica BOND RX Autostainer.  
Antibody Company Product Dilution Incubation (min)
Pan-cytokeratin (C-11) NeoMarkers 149-P 1:200 60
Ki67 (SP6) Thermo Fisher Scientific RM-9106-S1 1:500 60
CC3 Cell Signaling Technology 9661 1:200 60
pTyr397-FAK Abcam ab39967 1:4000 30
Merlin (NF2) (D1D8) Cell Signaling Technology 6995 1:1000 60
GFP Invitrogen A11122 1:1000 60
Table 3. Primary antibodies used for IHC using the DAKO Autostainer. 
Antibody Company Product Dilution Incubation (min)
CD31 Taylor Bio-Medical DIA-310 1:50 60
Total FAK BD Biosciences 610088 1:100 60
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and TRITC excitation, respectively. DAPI was excited using a UV 
laser, and signal was detected using internal photomultiplier tube 
detectors. Cell polarity was analyzed using ImageJ.
FLIM-FRET imaging of the FAK biosensor
For in vitro measurements of FAK activity, 1.5 × 105 TKCC05-FAK 
or TKCC10-FAK cells were seeded onto CDMs and allowed to 
adhere for 12 hours before FLIM-FRET imaging on CDMs. Imaging 
of TIF-FAK cells was performed on days 1, 7, and 12 of matrix con-
traction within the collagen matrix. For in vivo measurements of 
Enhanced cyan fluorescent protein (ECFP) fluorescence lifetime in 
subcutaneous xenografts, KPC-FAK cancer cells were injected into 
the flank of BALB/c-Fox1nuAusb mice. Two hours after treatment 
with vehicle or FAKi, tumors were surgically exposed using skin 
flap surgery. Imaging was performed using an inverted Leica DMS 
6000 SP8 confocal microscope with a Titanium-Sapphire femtosec-
ond laser cavity (Coherent Chameleon Ultra II) excitation source 
tuned to a wavelength of 840 nm for ECFP excitation. Signal was 
recorded using RLD-HyD detectors (using band-pass emission fil-
ters at 435/40 nm for SHG signal and 483/40 nm for FLIM). FLIM 
data were acquired with a PicoHarp 300 Time-correlated single 
photon counting (TCSPC) system (PicoQuant), and image sta-
bilization was performed using Galene (63). Fifty cells per condi-
tion for in vitro assays and five ROIs (512 m by 512 m) per tumor 
in vivo were acquired with a scan speed of 400 Hz, with an acquisi-
tion time of 2 min and 30 s and a pixel dwell time of 5 s. Analysis 
of ECFP lifetimes was performed using FLIMfit (80) by manual se-
lection of single-cell membrane ROIs and recording of the expo-
nential function fit to the fluorescence decay data. Reference 
lifetimes were calculated using a Chroma slide. Lifetime maps were 
generated from raw data with a smoothing by a 2 × 2 pixel kernel 
and application of a standard rainbow look-up table, with blue indi-
cating low ECFP fluorescence lifetime and red indicating high ECFP 
fluorescence lifetime. The background intensity threshold was set to 
the average background pixel value for each image to exclude areas 
without fluorescence lifetime measurement and is shown on the life-
time maps as black.
IVIS imaging
Orthotopic tumor growth and metastatic development were 
monitored via luciferase signal imaging on an IVIS Spectrum 
(PerkinElmer). Luciferin (150 mg/kg; Gold Biotechnology) was 
administered by intraperitoneal injection, 4  min before imaging. 
Anesthetized [2 liters of isoflurane, O2 (1 liter/min), with continuous 
vacuum to remove excess O2 and isoflurane] mice were placed on 
the IVIS stage, exposing the left flank, and the signal was acquired 
with open filters and small binning. Tumor burden was determined 
on the basis of total flux.
Macros
DAB coverage
This macro was used to separate DAB-stained area of total and 
pTyr397-FAK–stained sections from hematoxylin counterstain.
//ask user for directory source
dir=getDirectory("Select Directory");








filename = dir +list[i];
if(endsWith(filename, "tif")){
open(filename);
//store the image name in the nameStore Variable
nameStore = getTitle();
//Set the scale for results in um rather than in pixels
run("Set Scale...", "distance=125 known=50 pixel=1 
unit=um global");
//Split channels based on DAB staining
run("Colour Deconvolution", "vectors=[H DAB]");









run("Set Measurements...", "area limit redirect=None 
decimal=3");
run("Analyze Particles...", "size=50-Infinity circularity= 
0.00-1.00 show=Nothing display summarize");
//Threshold and calculate the area of DAB stain







run("Set Measurements...", "area limit redirect=None 
decimal=3");
run("Analyze Particles...", "size=50-Infinity circularity= 
0.00-1.00 show=Masks display summarize");
run("Measure");
//Save Overlaid Images of counts










saveAs("Text", dir + nameStore + "Area Summary.xls");
run("Close");
selectWindow("Results");
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This macro was used to quantify total Picrosirius red–stained area 
of tumor sections and CDMs. For organotypic matrices, the intensity 
of the stained area was analyzed using an in-house MATLAB 
(MathWorks, USA) code.





















This macro was used to quantify the average size of AIG clusters.




filename = dir + list[i];
if (endsWith(filename, "tif")){
open(filename);
//Stores the name of the title of the image. Files that are saved by this
//macro will use the name of the image at the beginning
nameStore = getTitle();
dir1 = File.directory;
//Set scale of image
run("Set Scale...", "distance=0.0118 known=1 pixel=1 
unit=um global");
//The RGB image is converted to 8-bit greyscale, and then 
thresholded to select for the positive stain.
run("8-bit");





run("Make Binary", "thresholded remaining black");
setAutoThreshold("Default dark");
run("Set Measurements...", "area limit redirect=None 
decimal=3");
run("Analyze Particles...", "size=500-infinity pixel show= 





saveAs("Results", dir+nameStore+" - Area Count.xls");
selectWindow("Summary");
saveAs("Summary". dir+nameStore+" - Area Count.xls");
run("Close All");
FUCCI cell cycle analysis
This macro was used to quantify the number of cells in G1-G0, 






run("Table...", "name="+tableTitle2+" width=600 
height=600");
print(tableTitle2, "\\Headings:Image Name\tGreen Cells\ 
tRed Cells\tYellow Cells\tPercent Green\tPercent Red\
tPercent Yellow");
setBatchMode(true); //batch mode on
for(i=0;i<list.length;i++){
filename = dir +list[i];
if(endsWith(filename, "tif")){
open(filename);
//store the image name in the nameStore Variable
nameStore = getTitle();
run("Split Channels");
selectWindow(nameStore + " (blue)");
close();













run("Set Measurements...", "area limit redirect=None 
decimal=3");
run("Analyze Particles...", "size=20-3000 pixel circularity= 
0.00-1.00 show=Masks display clear");
GreenCount= nResults;
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run("Set Measurements...", "area limit redirect=None 
decimal=3");
run("Analyze Particles...", "size=20-3000 pixel circularity= 









//Analyse Yellow (overlay) cells
selectWindow("Result of G1Mask");
run("Colour Deconvolution", "vectors=[User values] 
[r1]=-7.063186E-4 [g1]=-7.063186E-4 [b1]=0.9999995 












RedPercent = ((RedCount-YellowCount)/(GreenCount+ 
RedCount+YellowCount))*100;
YellowPercent = (YellowCount/(GreenCount+RedCount+ 
YellowCount))*100;
print(tableTitle2, nameStore + "\t" + GreenCount + "\t" 
+ RedCount + "\t" + YellowCount + "\t" + GreenPercent + 











Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.abh0363
View/request a protocol for this paper from Bio-protocol.
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